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1. General introduction 
 
1.1 Mycophenolic acid 
Mycophenolic acid (MPA) is an active fungal agent derived from Pencillium 
Brevicopactum and related fungi. MPA was discovered in 1893 by an Italian physician, 
Bartolomeo Gosio as an antibiotic against Bacillus anthracis (reviewed in [1]) and was 
named by Alsberg and Black in 1913 [2]. MPA selectively and competitively inhibits 
inosine monophphosphate dehydrogenase (IMPDH), which is a key regulatory 
enzyme in the de novo pathway of purine biosynthesis. IMPDH converts inosine 
monophosphate (IMP) to guanosine monophosphate (GMP), an important 
intermediate in the synthesis of DNA, RNA, proteins, and glycoproteins. Inhibition of 
IMDPH leads to cell cycle arrest in synthesis (S) phase due to the blocking of de novo 
guanosine nucleotide synthesis. MPA exhibits cytotoxic effects on all cell types 
including its main target, lymphocytic cells [3][4,5]. Lymphocytes presumably utilize a 
de novo pathway for purine biosynthesis while non-lymphocytic cells depend only 
partially on this pathway, and can utilize a salvage pathway [4]. In the salvage 
pathway, guanine obtained from the breakdown of nucleic acids is directly converted 
to guanosine monophosphate and used for purine synthesis [6]. Additionally, MPA has 
five fold more potent inhibitory action on IMPDH II, an isoform mainly expressed in B & 
T lymphocytes, than on IMPDH I, which is expressed in all body cells [4]. 
Consequently, the cytostatic effects of MPA on lymphocytes are greater than on other 
cell types, which contributes to the prevention of graft rejection, making MPA an 
especially useful immunosuppressant in transplantation medicine [3,4].  
 
MPA is marketed in two forms: the ester pro-drug mycophenolate mofetil (MMF; 
CellCept, Roche, Grenzach-Wyhlen, Germany) and enteric-coated mycophenolate 
sodium (EC-MPS; myfortic®; Novartis Pharma AG, Basel, Switzerland)  [7]. MMF 
gained approval by the United States Food and Drug Administration (FDA) in 1995 
for the prevention of renal, cardiac, and hepatic allograft rejection [8,9]. MPA is now 
the drug of choice in transplantation medicine for the prevention of acute rejection in 
patients undergoing allogenic renal, cardiac and liver transplantation [4,10]. 
Furthermore, MPA has proved to be effective in the treatment of autoimmune 
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EC-MPS 
AcMPAG 
MPA 7-O-glucoside  
 
6-o-desmethyl MPA 
MMF 
MPA 
MPAG 
disorders of the eyes and skin as well as in Wegener's granulomatosis and lupus 
nephritis [11-14], hypertension [15,16] and neuromuscular autoimmune diseases 
[17,18]. MPA has also been reported to possess anti-viral [19], anti-fungal [20], anti-
bacterial [1], anti-tumor [21], and anti-psoriasis [22,23] activities.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Chemical structure of MMF, EC-MPS, MPA, and their metabolites AcMPAG, MPA 7-
O-glucoside, and 6-o-desmethyl MPA. 
 
 
1.1.1 Metabolism 
 
MMF and EC-MPS is rapidly hydrolyzed by esterases in the gut, blood, liver, 
and kidney [24]. Maximal MPA plasma concentrations (Cmax) are generally reached 
within 1-1.5 hr and 1.5-2.5 hr after oral administration of MMF and EC-MPS 
respectively [7]. EC-MPS is insoluble in the acidic pH of the stomach but highly 
soluble in the neutral pH of the intestine. This effect is responsible for later peak 
concentrations seen after EC-MPS administration when compared to MMF [7,25]. 
Following intravenous administration, MMF is also rapidly hydrolyzed to MPA with 
Cmax achieved within approximately 1.58 hr and with an absorption half life of only a 
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few minutes [26].  The mean bioavailability of MPA is 81%-94% and 72% following 
administration of MMF and EC-MPS respectively [7,27], while the mean 
bioavailability of MPA after oral administration of MMF is estimated to be 94.1% 
relative to the intravenous route [28]. Trough plasma MPA concentrations are in the 
range of 0.3-3.4 mg/L [261]. MPA binds extensively (97-99%) to plasma albumin 
producing free fractions of only <3%. The free fraction of MPA is mainly responsible 
for the pharmacological effects of MPA [7,24,29,30].  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Metabolism of MPA. 
MMF and EC-MPS are hydrolyzed to their active form MPA in the GI tract. MPA then 
absorbed and subsequently glucuronated by UGT to MPAG in the hepatocytes. In addition, other 
metabolites including AcMPAG, MPA 7-O-glucoside, and 6-o-desmethyl MPA are also formed. MPAG 
is largely excreted into urine by hOATs while some is secreted into bile by MRP, where it is then either 
excreted into feces or reconverted to MPA by glucuronidases present in gut bacteria and returned to 
the systemic circulation (enterohepatic recycling). 
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Like many other xenobiotics, MPA undergoes glucuronidation, which is the 
major pathway for phase II metabolism for xenobiotics in humans [36]. MPA is 
conjugated by uridine diphosphate-glucuronosyltransferase (UGT) enzymes to form 
MPA glucuronide (MPAG) in hepatocytes, kidneys and intestinal mucosa [30,31]. 
UGT 1A9, UGT1A7, 1A8 and 1A10 are mainly responsible for MPAG formation [32]. 
Beside MPAG, other minor metabolites of MPA, such as 7-O-glucoside and the 
active acyl glucuronide of MPA (AcMPAG) are formed by UGT2B7 and 
miscellaneous UGTs respectively [32,33]. In addition, an oxidation product 6-O-
desmethyl MPA is formed by cytochrome P-450 (CYP3A4/5) [34]. The chemical 
structures of MPA, its pro-drugs, and metabolites are given in Figure 1.1. 
 
MPAG does not exhibit pharmacological activity but is present in 20 to 100-
fold higher concentrations than MPA in the blood [24] and achieves its Cmax in 1 hr 
after the MPA Cmax [251]. MPAG has a protein binding of 82% and has the capacity 
to interfere with the MPA-albumin binding. MPAG at high concentrations is known to 
displace MPA from its albumin binding sites, thus modulating the free fraction of 
MPA, which is important for the pharmacological activity of MPA [30,35].   
 
AcMPAG, a pharmacologically active metabolite, is believed to be responsible 
for some of the adverse effects of MPA [33,36,37]. Acyl glucuronides are formed by 
esterfication of carboxylic acid with glucuronic acid [36]. Such acyl glucuronides have 
been observed for several clinically useful therapeutic drugs including non steroidal 
anti-inflammatory drugs (NSAIDs) [36]. AcMPAG plasma concentrations are 10-20% 
of MPA concentrations [75,76]. Mean AcMPAG area under curve (AUC), over 12 hr 
is generally 10.3% of simultaneous MPA-AUC [75] and AcMPAG reaches its Cmax in 
1-3 hr following the Cmax of MPA {Schutz, 2000 680 /id}.  
 
MPA is eliminated from the body mainly through the kidneys. 93% of the orally 
administered dose of MMF is excreted in urine and 6% in the feces. MMF is 
predominantly (87%) excreted as MPAG in the urine and a small amount (<1%) as 
MPA. Like MMF, orally administered EC-MPS is also excreted maximally through 
urine, with 60% as MPAG and approximately 3% as MPA 1-7,4,8,9.  
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A proportion of MPAG is secreted into bile through multidrug resistant protein 
(MRP) transporters, specifically MRP2 [41]. MPAG then goes into the intestine where 
gut bacteria deglucuronidate MPAG to reform MPA, which is then reabsorbed back 
into systemic circulation [24,30]. This reabsorption is responsible for a second peak 
of MPA concentration detected in plasma 6 to 12 hr and 6 to 8 hr following oral 
administration of MMF and EC-MPS respectively [45]. This process is known as 
enterohepatic circulation and accounts for 10 to 60% of total MPA exposure 
[24,30,31,42]. The mean elimination half-life of MPA is 13 and 13–17 hr following oral 
administration of MMF and EC-MPS respectively [7,24]. The simplified overview of 
distribution and metabolism of MPA is shown in Figure 1.2. 
 
1.1.2 Cellular and adverse effects of MPA 
 
 
MPA causes the depletion of guanosine triphosphate (GTP) pools, which is 
assumed to be responsible for MPA associated anti-proliferative effects in vitro and in 
vivo [43,44]. Nucleotide inhibition leads to G1 cell cycle arrest and thus inhibits cell 
growth of immune (T and B lymphocytes) and non immune cells (smooth muscle 
cells, enthothelial cells, renal tubular and mesangial cells) in a dose-dependant 
manner [43,44,46-47]. MPA is also a potent anti-inflammatory agent which inhibits 
proliferation of immune cells, inhibits pro-inflammatory cytokines such as tumor 
necrosis factor alpha, interleukin 1 beta, interleukin-17, vascular endothelial growth 
factor alpha (VEGF-α), and blocks the migration of leucocytes to inflammation sites 
[48,49]. MPA has promising effects in reducing myofibroblast infiltration, collagen III 
deposition and inhibition of the proliferation of both immune (lymphocytes) and non 
immune (fibroblasts, vascular smooth muscle and tubular) cells which are involved in 
the development of fibrosis [50-52].  MPA inhibits tumor growth and metastasis 
through G1-S cell cycle arrest, induction of differentiation in a variety of human tumor 
cell lines, induces apoptosis, as well as suppress the glycosylation and expression of 
several adhesion molecules (integrins, ICAM-1, VCAM-1, E-selectin and P-selectin) 
which promote tumor metastasis [21,53-56].   
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Figure 1.3:  Adverse effects of MPA.  
Various proposed mechanisms of MPA associated side effects are highlighted such as (a) alteration in 
gene expression making individuals more susceptible to stress [78], (b) immunosuppression leading to 
opportunistic infections [58], (c) AcMPAG adduct toxicity results in ultrastructural abnormalities, 
metabolic dysfunction, and oxidative damage [58][36]. 
 
MPA is generally a well tolerated immunosuppressive agent and produces 
less nephrotoxicity compared to other immunosuppressives drugs (reviewed in [57]). 
GI toxicity is the common adverse effect of MPA, occurs in 20% of renal patients on 
MMF therapy, and is dose dependant (reviewed in [57]). Symptoms of GI toxicity 
include diarrhea, abdominal pain, nausea, anorexia, vomiting, [58-60], gastritis, 
esophagitis, duodenal ulcers, colonic ulceration [60,61], and small intestinal villous 
atrophy [62,63]. MMF can cause enterocolitis and a Crohn’s disease-like collitis 
syndrome [37,64,65].  
In addition to GI tract symptoms MPA can cause genitourinary symptoms such 
as frequency, urgency, dysuria, sterile pyuria, and hematuria. These symptoms have 
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reen reported to occur during the first year of MPA therapy (reviewed in [2,57]). In 
addition, MPA can also occasionally produce neurologic disturbances such as 
weakness, headache, tinnitus and insomnia (reviewed in [66]). Some cases of 
progressive multifocal leukoencephalopathy (PML) have been reported in patients on 
MMF therapy. These patients developed clinical features such as hemiparesis, 
apathy, confusion, cognitive deficiencies, and ataxia [67,68,68]. The occasional skin 
problems with MPA use include exanthematous eruptions, acne, pedal edema, 
urticaria, dishydrotic eczema, blistering hand dermatitis, and onycholysis (reviewed in 
[57,66]).  
MPA can cause cardio-respiratory toxicity causing dyspnoea, cough, chest 
pain, palpitations, hypertension, acute respiratory failure, pulmonary edema, 
pulmonary fibrosis and pneumonitis [57,69]. Metabolic disturbances are also reported 
in MMF treated patients. Findings in these patients includes hypercholesterolemia, 
hypophosphatemia, hypokalemia, hyperkalemia, hyperglycemia (reviewed in [57,66]). 
There have been reports of mild, dose-related haematologic effects occurring in 5% 
of patients. Findings include anemia, leucopenia, and thrombocytopenia (reviewed in 
[2,57]). Pure red cell aplasia (PRCA) has been observed in some patients treated 
with MPA in combination with other immunosuppressive drugs [70]. An increased 
incidence of infectious complications occurs in 2% of renal and cardiac transplant 
patients and in 5% of hepatic transplant patients treated with MPA (reviewed in [57]). 
Like other immunosuppressive therapies, opportunistic infections occur in up to 40% 
of transplant patients given MMF (reviewed in [66,71]). Several viral, bacterial and 
fungal complications have been observed, including infection with herpes simplex 
virus, herpes zoster virus, human herpes virus type 6,  papillomavirus, aspergillosis, 
encephalitis, streptococcus B septic shock, recurrent E.coli associated epididymitis, 
pediatric disseminated varicella, candidiasis, cryptococcosis, mucormycosis 
pneumocystis carinii pneumonia, and intestinal microsporidosis (Reviewed in 
[3,56,74]).  
Diarrhoea is the most common GI adverse effect caused by MPA but the 
exact mechanism responsible for this have not yet been clearly defined [72]. Several 
mechanisms have been suggested to be responsible for the adverse events 
associated with MPA therapy including direct cytotoxic effects on GI cells, release of 
pro-inflammatory cytokines by AcMPAG [73,74], and formation of AcMPAG protein 
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adducts [75]. Covalent AcMPAG-protein adducts are formed through two pathways; 
transacylation and glycation. Transacylation involves direct bounding of an aglycone 
moiety to the proteins while the glycation mechanism involves intramolecular re-
arrangement resulting in a open-chain conjugate with a free aldehyde group which 
binds with the amino group on various proteins [36,77].  
 
AcMPAG adducts may cause cellular toxicity through a number of proposed 
mechanisms. These adducts may modify protein structure and thus interfere with 
normal cell function, or they may activate the immune system resulting in 
hypersensitivity reactions or autoimmunity. Furthermore, AcMPAG adducts cause 
oxidative stress via glutathione depletion [58][36]. Previously, it was demonstrated 
that AcMPAG forms covalent protein adducts in the kidney, liver and intestine of rats 
treated with MMF [76,77]. The proteins involved are associated with diverse cellular 
functions. Another study revealed that MMF down-regulates mRNA expression of 
polymeric immunoglobulin receptor (resulting in decreased protection against 
invading pathogens and reactive drugs), catalase (cells were more prone to oxidative 
stress), and CCAAT/enhancer-binding proteins (interference with the defence system 
against free radicals) [58,78]. The adverse effects of MPA therapy are summarized in 
Figure 1.3. 
 
1.2 Intestinal epithelial barrier  
 
The mammalian intestine is lined with a single layer of specialized simple 
columnar epithelium that separates the intestinal lumen from the underlying lamina 
propria [79,80]. The intestinal lining consists of proliferative crypts, which contain 
intestinal stem cells, and villi, which contain differentiated specialized cell types such 
as the absorptive enterocytes, mucous-secreting goblet cells, and hormone-secreting 
enteroendocrine cells [81] (reviewed in [82]). In addition, there are Paneth cells which 
are differentiated cells at the bottom of crypts bottom that perform several functions 
including limiting gut microbial populations by secreting defensins, (antimicrobial 
peptides) and protecting the intestinal lining from bacterial toxins [80].  
 
The intestinal epithelium represents the major contact between a person and 
their external environment and covers an extensive surface area of >300 m2 [83]. 
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Structural components of the intestinal barrier include the unstirred water layer, the 
hydrophobic mucosal surface, the surface mucous coat, epithelial factors (tight 
junctions), and endothelial factors [84]. The intestinal epithelium has two vital 
functions. It selectively filters, allowing the absorption of nutrients, electrolytes, and 
water from the intestinal lumen into the circulation while it serves as a barrier to 
prevent luminal pro-inflammatory factors, luminal pathogens and their antigens or 
toxins from invading the tissues [84-87]. In addition, the stirred water layer plays a  
role in transport of many nutrients and drugs, especially lipid-soluble compounds 
[84]. Mucus from goblet cells provides a protective layer against the physical friction, 
chemical digestion, and adhesion of bacteria. In addition, it also acts as a diffusion 
barrier [84,88]. The hydrophobicity of the mucosal surface acts as an important 
barrier to bacterial and other factors within the gut lumen. Many factors such as 
nonsteroidal anti-inflammatory drugs (NSAIDs), dextran sodium sulfate, 
trinitrobenzenesulfonic acid, lipopolysaccharide (LPS) and ammonium [89] can 
decrease this hydrophobicity.  
 
The epithelial layer constitutes the key component of intestinal barrier. It acts as 
a selectively permeable filter allowing the transport of essential dietary nutrients, 
electrolytes, and water from the intestinal lumen into the circulation [84,90].  In 
addition, the intestinal epithelia controls chloride permeability which is responsible for 
secretion of protective fluids into the intestinal lumen which limits bacterial 
colonization and entry of toxins into the intestinal cells [91]. Another important 
function of the intestinal lining is its secretion of local immunoglobulins such as 
epithelial secretory immunoglobulin-A (IgA) which targets antigens at the mucosal 
surface, and constitutes a humoral component of the mucosal immune system [92-
94].  
Permeability of the intestinal epithelium is regulated via 
transepithelial/transcellular and paracellular pathways. Transcellular transport is an 
active process and involves transport of water, amino acids, electrolytes, short-chain 
fatty acids, and sugars across the plasma membrane by specific ion channels and 
transporters [15,16][95]. Paracellular transport is a passive process which involves 
the movement of solutes and water across the intercellular space and is regulated by 
intercellular complexes. Paracellular transport is determined by molecular size or the 
ionic charge or both and is mainly regulated by tight junctions (TJ) [95,96].   
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1.2.1 Tight junctions  
 
Intestinal epithelial cells are connected to one another by adhesive junctional 
complexes which serve as a physiological and structural paracellular barrier. 
Components that constitute the multimolecular junctional complex include 
desmosomes, adherens junctions, and TJs [97,98]. TJ, the most apical component of 
the junctional complex are generally considered to be the major barrier to the 
passage of molecules between adjacent cells and through the intercellular space. 
The TJ barrier is not absolute but is selectively permeable and is able to discriminate 
between solutes on the basis of size and charge. TJ complex contains more than 
forty proteins, having various functions [99]. The structure of TJ was first described 
with the help of electron microscopy [100]. TJ consist of transmembrane proteins 
(JAMs, occludin and claudins), adaptors (ZO (type 1-3), MAGI (type 1-3), PAR 3/6, 
cingulin, PATJ and MUPP1), regulatory proteins (Rab 13, Rab 3b, G proteins, PKC, 
PP2A and PTEN), and both transcriptional and post-transcriptional regulators 
(symplekin, ZONAB, and huASH1). All these proteins interact with each other to form 
a complex protein network [101,102], responsible for TJ functions including their 
interaction with F-actin [103]. The basic architecture of TJ is shown in Figure 1.4. All 
of the TJ proteins listed above play an important role in the structure and function of 
TJ, but only a brief description of the function of some TJ proteins ( ZO-1, occludin, 
and claudin), which have been extensively studied in the context of TJ disruption 
[104] are described below.  
 
ZO, the first TJ-associated protein to be identified [105], belongs to the 
membrane associated guanylate kinase family (MAGUK) and contains three N-
terminal PDZ repeats, an SH3 domain, and a C-terminal region homologous to 
guanylate kinases [106]. There are different isotypes of ZO including ZO-1, ZO-2 and 
ZO-3 with a variety of cellular functions. ZO-1 is a 210-225 KDa peripheral 
membrane protein and is a major constituent of the cytoplasmic domain of TJ. The C-
terminal domain of ZO-1 interacts with other TJ proteins including claudins [107]. ZO-
1 is also in close association with actin cytoskeleton responsible for linking 
transmembrane proteins of the TJ to the actin cytoskeleton that plays a regulatory 
role in TJ actions. The C-terminal portion of occludin, claudin, ZO-2, and ZO-3 
interact closely with the N-terminus of ZO-1. Additionally, the C-terminal half of ZO-1 
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interacts with F-actin regulating cytoskeleton [107,108]. The expression and 
distribution of ZO proteins are regulated by myosin light chain kinase (MLCK) and 
their alteration can lead to defective function of epithelial barriers [109]. The down-
regulation and redistribution of ZO-1 has been observed in TJ disruption conditions, 
such as those involving cytokines [110,111], ethanol [112] and oxidants [113].  
 
Occludin is a 60 KDa protein and was identified as the first among 
transmembrane TJ proteins in 1993 [114,115]. Occludin is a member of the Marvel 
(MAL-related proteins for vesicle trafficking and membrane link) domain containing 
protein family [116]. Occludin has a tetraspan structure that constitutes its 
extracellular strand within TJ and amino- and carboxy-terminal chains projecting into 
the cytoplasm [117]. The interactions of occludin with various intracellular TJ 
proteins, including ZO-1, ZO-2, and ZO-3 have been well documented [118]. 
Occludin plays an important role in regulating TJ dynamics as demonstrated by the 
fact that its depletion leads to increases in the permeability of larger-sized molecules 
shown in both in vitro and in vivo intestinal models [119]. The down-regulation of 
occludin proteins, associated with increased permeability has been observed in 
several inflammatory bowel diseases such as Crohn's disease, ulcerative colitis, and 
celiac disease [120-122], as well as in animal models of inflammatory bowel disease 
[123,124]. It has been proposed that a decrease in intestinal occludin expression 
may be an important mechanism responsible for increased intestinal epithelial TJ 
permeability. Occludin in epithelial cells is highly phosphorylated on serine and 
threonine residues and its phosphorylation plays a critical role in the regulation of TJ 
integrity. Occludin phosphorylation is regulated by the balance between protein 
kinases (eg. c-Src, PKCζ, and PKCλ/ι,) and protein phosphatases (eg. PP2A, PP1, 
and PTP1B) [125-127]. Occludin has also been reported to be phosphorylated at 
tyrosine which has been proposed to be implicated in disruption of TJs by various 
toxins such as hydrogen peroxide and acetyladehyde [128,129].   
 
Claudins are 20-27 KDa integral membrane TJ proteins that contains four 
hydrophobic transmembrane domains which have a cytoplasmic N terminus, two 
extracellular loops, and a C-terminal cytoplasmic domain. The claudin family is a 
multigene family comprised of at least 24 members [130]. On the basis of their role in 
controlling permeability, claudins has been divided into two sub-categories, 
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paracellular barrier forming claudins and paracellular, ion permeability forming 
claudins. Both are vital for proper and tissue-specific functioning of the TJs; making 
claudins a critical player in regulation of paracellular function [131,132]. The carboxy 
terminus of claudins binds to PDZ domains of proteins including those of the ZO 
proteins [107]. In addition, interaction of claudin-1 with ZO-1 is critical for ZO-1 
integration into epithelial TJs [133]. Claudin isotypes 1 to 5 are present in the 
intestinal cells in various intestinal regions [134,135].  Down-regulation of claudin 1 is 
believed to be linked to the TJ disruption in inflammatory mucosa by Crohn's 
diseaseand ulcerative colitis and is believed to be associated with enhanced 
paracellular permeability [136]. Claudin 4 down-regulation has also been observed in 
collagenous colitis, characterized by barrier defects and associated with reduced net 
Na+ and Cl- absorption [137].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Intestinal epithelial barrier. 
Schematic diagram of intestinal epithelial cells showing tight junctions (TJ), adherens junctions (AJs), 
desmosomes and gap junctions. The TJs are positioned at the most apical parts of the plasma 
membranes of entrocytes, whereas AJs and desmosomes are present mainly at the basal parts of the 
lateral membranes. TJ and AJ are linked to actin and play an important role in regulation of intestinal 
permeability (Left panel). The molecular components of epithelial tight junctions (TJs) are outlined 
(right panel), and consist of transmembrane proteins (occludin, claudins and JAMs), adaptors (ZO (1-
3), PAR 6, and PATJ), regulatory proteins (Rac, cdc42, RhoA, and PKC), and other associated 
proteins. Occludin, claudins and JAMs are linked to the zona occludens, and they are connected to 
actin forming the main TJ assembly. Adopted from (Aktories K and Barbieri JT 2005, Nat Rev 
Microbiol) [138]. 
 
 
 18 
          TJ defects have been described in several patho-physiological conditions such 
as brain diseases [139,140], pulmonary inflammation, allergic rhinitis [141], 
obstructive jaundice [142], kidney diseases [143,144], diabetic retinopathy [145], 
cancers [146], blood-borne metastases [140,147] and bowel diseases [148-150]. 
Intestinal epithelial barrier dysfunction is a major factor contributing to the 
predisposition to inflammatory diseases, including food allergy, IBD, and celiac 
disease. The presence of environmental factors in the intestinal lumen and 
inappropriate host immune responses are key determinants of the development of 
IBD [87,148]. In IBD, epithelial barrier function is impaired leading to either diarrhoea 
because of a leaky flux mechanism or translocation of toxins and macromolecules 
into intestinal cells causing associated dysfunction [151]. 
1.2.2 Factors modulating intestinal permeability   
 
Several endogenous molecules such as glucose [153], hormones [154], 
nucleotides [155], and growth factors [156-158] provide physiological modulation of 
TJ permeability. In addition, a growing list of pathological agents has been suggested 
as etiologic factors in several diseases as a result of causing increased mucosal 
permeability [159]. Dietary components are crucial in the regulation of barrier integrity 
(reviewed in [160]). Gliadin, a glycoprotein present in wheat, is the key factor in the 
pathogenesis of celiac disease and is responsible for TJ disruption leading to 
increased permeability [161]. Several dietary components have been found to 
increase TJ permeability including: cayenne pepper (Capsicum frutescens), paprika 
(Capsicum anuum), galangal (Alpinia officinarum), marigold (Tagetes erecta), Acer 
nikoense, and hops (Humulus lupulus) (reviewed in [160]). In contrast, black pepper 
(Piper nigrum), green pepper, nutmeg, bay leaf extracts, linden (Tilia vulgaris), star 
anise (Illicium anisatum), Arenga engleri, and black tea (Camellia sinensis) have 
been found to decrease paracellular flux and increase transepithelial resistance 
(TER) (reviewed in [160]). 
 
Pro-inflammatory cytokines have also been proposed as pathophysiological 
stimuli which trigger several cellular pathways leading to pathological conditions 
including bowel diseases [110,111,162-166]. For example, TNFα modulates epithelial 
barrier properties and has a critical role in IBDs [167] and graft-versus-host disease 
[152]. TNFα up-regulates MLCK which acts as the central player in TNFα induced 
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barrier loss, both in vitro [168] and in vivo [150,169]. Additionally, TNFα has also 
been shown to be involved in the down regulation of apical Na+-H+ exchange, which 
then is linked to the development of diarrhoea [169,170]. Mast cells (MC) have been 
reported to regulate intestinal permeability, as suggested by the fact that their 
degranulation results in blood flow modulation, as well as increased epithelial and 
endothelial permeability, mucosal secretion, gastrointestinal tract motility, 
immunologic reactions, and angiogenesis (reviewed in [84] ). Several physiological 
and pathological conditions have been reported to be associated with MC mediated 
intestinal permeability including food allergy, irritable bowel syndrome, and after 
stressful conditions [171,172]. Intracellular mediators including nitric oxide (NO) 
regulate barrier properties by altering the function of epithelial cells and the GI 
microcirculation [173]. The activity and synthesis of NO is increased by endotoxin 
(LPS), cytokines, and ethanol (EtOH), which results in barrier dysfunction via protein 
oxidation, nitration, S-nitrosylation, cGMP activation, and cellular energy depletion 
(reviewed in [84]). 
 
Epithelial-microbe interactions are responsible for alterations in the structure 
and function of the epithelial barrier, regulation of fluid and electrolyte secretion, and 
modulation of  inflammatory signalling (reviewed in [174]). More than 400 microbial 
species that have a profound impact on gut physiology reside in the gastrointestinal 
lumen [80]. Pathogenic bacteria, such as Escherichia coli, Klebsiella pneumoniae, 
Streptococcus viridans, Clostridium difficile, Bacteroides fragilis, Vibrio cholerae, and 
Helicobacter pylori, as well as viruses and parasites (giardia) can disrupt the 
intestinal barrier (reviewed in [84]). Beneficial bacteria:however, such as 
Lactobacillus brevis maintain TJ and reduce intestinal permeability [175]. 
Psychological stress is another factor responsible for alterations in epithelial barrier 
physiology (reviewed in [84]). Various parts of brain, brain stem, various CNS 
afferents, and the neuro-endocrinal system are proposed to be involved in the stress 
response. During psychological stress corticotrophin-releasing factor (CRF) is 
released, which triggers the enteric nervous system that causes alterations in gut 
motility, exocrine and endocrine functions, and the microcirculation (reviewed in 
[176]). Oxidative stress is caused largely by reactive oxygen (ROS) species such as 
hydrogen peroxide (H2O2), nitric oxide, peroxynitrite and hypochlorous acid which 
disrupt the epithelial and endothelial barrier function by destabilizing TJs [177]. 
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1.2.3 Regulation of TJ structure and function 
 
Regulation of the assembly, disassembly, and maintenance of TJ structure is 
highly dynamic and is influenced by diverse protein-protein interactions that respond 
to both extra-cellular and intra-cellular physiological, pharmacological, and 
pathophysiological stimuli. TJ regulation is controlled by several signalling proteins, 
including tyrosine kinase, Ca+2, phospholipase C (PLC), protein kinase C (PKC), 
calmodulin, mitogen-activated protein kinase (MAPK), MLCK, the Rho family of small 
GTPases, adenosine, 3’,5’-cyclic monophosphate (CAMP), and heterotrimeric G 
proteins [178-182]. Actin has a vital role in the structure and function of TJ. Multiple 
TJ components interact with the actin cytoskeleton and regulate the permeability of 
TJs [183,184]. Reorganization of the actin cytoskeleton as a result of interactions 
between transmembrane proteins and the actomyosin ring [178,183,185,186] and as 
well as the phosphorylation state of TJ proteins are both critically involved in 
alterations in TJ physiology [187,188]. Members of the Rho family GTPase (Rac, 
Rho, and Cdc42) have also been shown to be able to reorganize the actin 
cytoskeleton and modulate TJ physiology [179,189-191]. Changes in the 
phosphorylation status of TJ proteins such as ZO, occludin, E-cadherin, β-catenin, 
and claudins act as a molecular switch that regulates TJ structure and function 
[125,187,188,192,193].  
 
MLC phosphorylation is an  important regulator of barrier function in health 
and disease [194]. Increased MLC phosphorylation leads to the rearrangement of TJ 
proteins (ZO-1, occludin, claudin-1 and claudin-4), disruption of perijunctional F-actin, 
and increases TJ permeability [103,184]. The main pathways associated with MLC 
phosphorylation are controlled either directly by MLCK activity or indirectly by Rho 
kinase mediated inhibition of phosphatase [182]. MLCK mediated MLC 
phosphorylation is sufficient to trigger downstream events necessary for barrier 
regulation and has a central role in many diseases that are characterized by 
intestinal barrier dysfunction (reviewed in [170]). Increased MLCK expression or 
activity has been observed in GI pathology following TNF α [169], interleukin 1β 
[195,196], lipopolysaccharide [197], and ethanol [112,198] exposure. Similar 
increased MLCK activity is observed after exposure to virulence factors associated 
with GI infections with Enteropathogenic Escherichia coli (EPEC) [199,200] and 
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Helicobacter pylori [201,202], as well as parasitic diseases like giardiasis [203]. The 
role of Rho family of small GTPases has been described in the regulation of TJ 
structure and function including the perijunctional actomyosin ring [194,204]. ROCKs 
regulate the phosphorylation of MLC by inactivating MLCP (myosin light chain 
phosphatase), which is involved in decreasing MLC phosphorylation [191]. ROCK 
inhibition causes the redistribution of F-actin structures and modulates TJ 
permeability. In addition, ROCK co-localizes with the ZO-1 and its inhibition prevents 
proper localization of TJ proteins during TJ assembly [204].  
 
PKC is an important member of the serine-threonine kinases family which 
regulate epithelial barrier structure and function. PKC modulates the expression of 
subcellular localization and phosphorylation states of TJ proteins which alters  barrier 
dynamics [206]. PKC proteins are also involved in various signal transduction 
pathways such as the Toll-like receptor 2 (TLR2) pathway. Activation by PKC 
isoforms results in increases in TER and redistribution of ZO-1 (reviewed in [160]). 
PKC also interacts with MLCK. PKC phosphorylates MLCK  which leads to 
decreases in MLC phosphorylation, reduces tension on the perijunctional actomyosin 
ring (PAMR), and increases permeability [207]. The MAPK pathway is a major 
intracellular signalling pathway involved in cell growth, differentiation, and TJ 
regulation [208]. Several growth factors, cytokines, and oxidative stresses are 
involved in the stimulation of the MAPK pathway (reviewed in [160,209]). Members of  
MAPK have been implicated in modulation of TJ structure and function since 
extracellular signal regulated kinases (ERK) interact directly with the C-terminal 
region of occludin to prevent H2O2-induced disruption of TJ [208]. 
 
1.2.4 Caco-2 cells as an in vitro model for intestinal epithelial 
integrity  
A number of both in vitro and in vivo experimental models are being used to 
study the integrity of TJs [210-213][214,215]. Caco-2 is one of the most widely used 
intestine cell models for in vitro studies of intestinal barrier functions [211,216,217], 
intestinal absorption, and toxicity of xenobiotics [216-218]. Caco-2 cells were first 
generated from the differentiated colon adenocarcinoma of a 72-year old patient 
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[219]. Caco-2 cells grown in culture usually reach confluency within 3-6 days, a 
stationary growth phase after 10 days [220], and complete their differentiation within 
20 days [221]. Once differentiated these cells exhibit properties similar to enterocytes 
both structurally, bio-chemically, and functionally including having microvilli, 
intercellular junctions, nutrient transporters, efflux transporters, and enzymes 
(alkaline phosphatase, sucrase isomaltase and aminopeptidase) [222,223]. Caco-2 
cells also express various transport and metabolizing enzymes such as cytochrome 
P450 isoforms and UDP-glucuronosyltransferases, sulfotransferases and 
glutathione-S-transferases [224,225]. Although, most Caco-2 properties resemble 
those of enterocytes, some differ. Caco-2 cells lack the crypt-villus axis (which is 
important for in vivo transport) and mucus producing goblet cells (leading to a lack of 
prominent mucus layers [226-228]).  
Transepithelial electrical resistance (TER) and paracellular permeability to 
tracers molecules are two parameters that are commonly used to investigate the 
integrity and function of the TJ in in vitro models such as Caco-2 monolayers 
[213,229-232]. Usually, TJ barriers limit the ionic diffusion through cell monolayers, 
which creates a potential difference that is measured as transpithelial resistance 
(TER). TER has a direct relationship with TJ integrity. The greater the TER, the more 
intact the TJ [223,233,234]. Paracellular permeability of tracers in cell layers is 
measured by the diffusion rate of such tracers from apical to basal or vice versa. 
Paracellular flux is inversely related to TJ integrity (ie. increased paracellular flux 
suggests TJ disruption [213,233]). A variety of paracellular flux markers are used to 
investigate the effects of physiological and pathological agents on TJ integrity. The 
most frequently used paracellular markers include polyethylene glycols (PEG), 
fuorescein-5 and -6 sulfonic acid [235], inulin [119,236,237], fluorescein 
isothiocyanate dextrans (FITC-dextran), urea, mannitol, L-glucose [119,237], 
raffinose [238], atenolol [239] and lucifer yellow [240]. Size, shape, and charge of the 
solutes used control the permeability properties of any particular paracellular marker 
[233,241].  
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1.3 Rationale for the proposed research  
 
Mycophenolic acid is a frequently used immunosuppressive agent and has a 
wide range of pharmacological actions. The present study was undertaken to identify 
novel molecular targets of MPA using a comprehensive 2-DE based expression 
proteomics approach. Whole cell lysates from HEK-293 cells which had been 
exposed to MPA were resolved by 2-DE, and differentially expressed proteins were 
identified by QTOF MS/MS analysis. In an attempt to examine effects with possible 
clinical relevance on a regulated protein, myosin light chain 2 (MLC2), we 
investigated the effects of MPA on TJ integrity using Caco-2 monolayers as a colonic 
cell culture model. After employing various physiological assays as well as 
immunoblotting and immunoflourescence analyses, we found that exposure to 
therapeutic concentrations of MPA modulated tight junction physiology via MLC2 
phsophorylation. The current study may help to understand the etiology of MPA 
associated adverse intestinal effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
2. Differential proteome analysis of human 
embryonic kidney cell line (HEK-293) following 
mycophenolic acid treatment 
Muhammad Qasim1, 2, Hazir Rahman1, 2, Michael Oellerich1, Abdul R. Asif1 
1. Department of Clinical Chemistry, University Medical Centre Goettingen, 37075, 
Goettingen, Germany. 
2. Department of Microbiology, Kohat University of Science and Technology, 26000, 
Kohat, Pakistan.       
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Published in “Proteome Science 2011, 9:57 
 
 
 
 
 
 25 
2.1 Abstract 
Mycophenolic acid (MPA) is widely used as a post transplantation medicine to 
prevent acute organ rejection. In the present study we used proteomics approach to 
identify proteome alterations in human embryonic kidney cells (HEK-293) after 
treatment with therapeutic dose of MPA. Following 72 hours MPA treatment, total 
protein lysates were prepared, resolved by two dimensional gel electrophoresis and 
differentially expressed proteins were identified by QTOF-MS/MS analysis. 
Expressional regulations of selected proteins were further validated by real time PCR 
and Western blotting. The proliferation assay demonstrated that therapeutic MPA 
concentration causes a dose dependent inhibition of HEK-293 cell proliferation. A 
significant apoptosis was observed after MPA treatment, as revealed by caspase 3 
activity. Proteome analysis showed a total of 12 protein spots exhibiting differential 
expression after incubation with MPA, of which 7 proteins (complement component 1 
Q subcomponent-binding protein, electron transfer flavoprotein subunit beta, 
cytochrome b-c1 complex subunit, peroxiredoxin 1, thioredoxin domain-containing 
protein 12, myosin regulatory light chain 2, and profilin 1) showed significant increase 
in their expression. The expression of 5 proteins (protein SET, stathmin, 40S 
ribosomal protein S12, histone H2B type 1 A, and histone H2B type 1-C/E/F/G/I) 
were down-regulated. MPA mainly altered the proteins associated with the 
cytoskeleton (26%), chromatin structure/dynamics (17%) and energy 
production/conversion (17%). Both real time PCR and Western blotting confirmed the 
regulation of myosin regulatory light chain 2 and peroxiredoxin 1 by MPA treatment. 
Furthermore, HT-29 cells treated with MPA and total kidney cell lysate from MMF 
treated rats showed similar increased expression of myosin regulatory light chain 2. 
The emerging use of MPA in diverse pathophysiological conditions demands in-depth 
studies to understand molecular basis of its therapeutic response. The present study 
identifies the myosin regulatory light chain 2 and peroxiredoxin 1 along with 10 other 
proteins showing significant regulation by MPA. Further characterization of these 
proteins may help to understand the diverse cellular effects of MPA in addition to its 
immunosuppressive activity.  
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2.2 Introduction 
 
Mycophenolic acid (MPA) is a frequently used immunosuppressant for the 
prevention of acute rejection in patients undergoing allogenic renal, cardiac, lung, 
and liver transplantations [4,10]. MPA is a selective, reversible and uncompetitive 
inhibitor of inosine monophosphate dehydrogenase (IMPDH), a key regulatory 
enzyme in the de novo pathway of purine synthesis. It exhibits cytotoxic effects on 
most of the cell types, but exerts greater effects on T and B lymphocytes, thus 
preventing solid organ rejection [4]. IMPDH inhibition by clinically relevant 
concentration of MPA results in guanine nucleotide depletion which is associated 
with G1 cell cycle arrest. MPA also triggers apoptosis by up-regulating pro-apoptotic 
proteins (p53, p21 and bax) and down-regulating proteins that are important for cell 
cycle progression, such as bcl-2, survivin p27 and c-myc [242]. IMPDH type II is 
significantly over-expressed in several tumor cells, for this reason IMPDH could be 
considered as a potent target for anti-cancer therapy, as well as immunosuppressive 
chemotherapy [243].  
 
MPA and its metabolites effect most of the cellular functions by influencing 
biological pathways, like apoptosis [244], immune associated signaling [245] and 
general cell signaling pathways involving mitogen-activated protein kinases, 
extracellular-signal regulated kinases, c-Jun N-terminal kinases, p53 and Rho-
associated protein kinase [244,246,247]. Collectively, MPA possesses anti-microbial, 
anti-inflammatory, anti-fibrotic, pro-apoptotic [4], anti-angiogenic, anti-cancerous 
[248] and anti-oxidant activities [249]. Due to MPA diverse therapeutic activities in the 
cell, it is also used for the treatment of dermatological diseases, neuromuscular 
diseases and autoimmune disorders such as lupus [248,250]. Gastrointestinal tract 
(GIT) complications i.e., diarrhoea, nausea, abdominal pain, vomiting, anorexia, 
gastritis, intestinal ulceration and small intestinal villous atrophy are common 
complication for some transplant patients on MPA therapy. Other MPA associated 
adverse effects are anemia, myelosuppression and risk of opportunistic infections 
[251]. The exact molecular mechanism of MPA organ toxicity is unknown, but 
possible mechanisms include direct toxicity by its anti-proliferative effect, 
opportunistic infections due to myelosuppression and toxicity, and acyl MPA 
glucuronide (AcMPAG) proteins adduct formation [36,251]. 
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Here we use HEK-293 cell line to uncover cellular protein response to the 
exposure of clinical dose of MPA. In the present study we used a proteomics based 
approach to resolve proteins of total cell lysates on two dimensional electrophoresis 
(2-DE) gels following treatment with DMSO and MPA. The differentially expressed 
proteins were in-gel tryptic digested and identified by QTOF-MS/MS analysis. 
Several proteins were identified with modified expression in response to MPA 
treatment which might be helpful to broaden our understanding regarding the cellular 
effects of MPA. 
 
2.3 Materials and methods 
 
2.3.1 Reagents 
 
Cell culture media (DMEM and MacCoy´s), fetal calf serum (FCS), phosphate 
buffer saline (PBS), penicillin and streptomycin were purchased from PAA 
Laboratories, Colbe, Germany. Urea, thiourea, dithiothreitol (DTT), trypsin, 
triflouroacetic acid (TFA), sodium carbonate, ammonium bicarbonate, MPA and 
DMSO were purchased from Sigma-Aldrich, Steiheim, Germany. Acetonitril (ACN) 
was obtained from Promochem, Wasel, Germany. CHAPS was obtained from 
AppliChem, Darmstadt, Germany. Ampholytes, protein assay kit and immobilised pH 
gradient strips (IPG strips) were procured from Bio-Rad, Munich, Germany, while 
protease and phosphatase inhibitor cocktails were purchased from Roche, 
Mannheim, Germany. Bromophenol blue and trizma base were obtained from Carl 
Roth, Karlsruhe, Germany. Sodium dodecyl sulfate (SDS) was obtained from Serva, 
Heidelberg, Germany. Glycerin, potassium ferricynaide and sodium thiosulfate were 
purchased from Merck, Darmstadt, Germany and formic acid from BASF, 
Ludwigshafen, Germany.  
 
2.3.2 Cell culture  
 
HEK-293 and HT-29 cell lines were purchased from German collection of 
microorganisms and cell cultures (DSMZ), Braunschweig, Germany. The cells were 
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grown in 75 cm2 culture flasks (Sarstedt, Nuemberecht, Germany) and maintained in 
culture at 37°C in 95% humidity, 20% O2 and 5% CO2.  DMEM and MacCoy’s media 
supplemented with L-glutamine, 10% fetal calf serum, 100 U/mL penicillin, and 0.1 
mg/mL streptomycin was used to grow HEK-293 and HT-29 cells respectively.  
 
2.3.3 Proliferation assay 
 
Briefly, cells were grown in 96 well plates at a density of 3.5 X 104 cells/well at 
least 24 h prior to the start of the experiment. The cells were then incubated with 
DMSO (control) or 0 to 100 µmol/L MPA for a period of 72 hr. After completion of 
incubation, proliferation was determined using ELISA based BrdU cell assay (Roche 
Diagnostics) according to manufacturer’s recommendations. Four independent 
experiments were performed. IC50 values were calculated by a Grafit software 
package, version 5 (Erithacus Software, London, UK).  
 
2.3.4 Sample preparation for proteome analysis 
 
The HEK-293 and HT-29 cells were grown for 24 hr followed by treatment with 
DMSO or MPA (7.5 µmol/L and 10 µmol/L for HEK-293 and HT-29 respectively) for 
72 h. Cells were harvested by scraping and were washed three times with ice cold 
PBS. After washing, cells were pelleted down at 250 x g for 10 min and lysed in a 
buffer containing 7 mol/L urea, 2 mol/L thiourea, 4% w/v CHAPS, 2% ampholyte pH 
3-10 and 1% DTT. The lysates were centrifuged and protein content was measured 
by Bradford assay [252] using Bio-Rad protein reagent (Bio-Rad, Munich, Germany) 
according to manufacturer’s instructions. Sample aliquots were kept at -80°C until 
further use. Protein lysate was prepared from 21 days MMF treated adult female 
Wistar rat’s kidney according to the previously reported protocol [253] and were used 
for Westernblotting. 
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2.3.5 2-DE 
 
The 2-DE was performed as described by Gorg et al 2000 [254] with some 
minor modifications. Protein samples of HEK-293 cell (110 µg) were mixed with 
rehydration buffer (7 mol/L urea, 2 mol/L thiourea, 4% CHAPS, 0.2% ampholyte [pH 
3-10], and 0.2% DTT) containing trace amount of bromophenol blue to a total volume 
of 350 µL. Samples were applied to linear IPG strips [pH 3-10], Bio- Rad) for 1 hr and 
then covered with mineral oil for passive rehydration overnight at room temperature. 
Iso-electric focusing (IEF) was performed in Protean IEF cell (Bio-Rad) with a 
program of 1 h at 100 volts, 1 h at 500 volts, 2 hr at 1000 volts and 8000 volts with a 
total of 32000 volts-hr. For the second dimension electrophoretic separation, focused 
strips were equilibrated for 30 min at room temperature in a buffer containing 50 
mmol/L Tris-HCL [pH 8.8], 6 mol/L urea, 30% v/v glycerol, 2% SDS and 10 g/L DTT 
followed by an identical incubation but replacing DTT with 40 g/L iodoacetamide. The 
proteins in the equilibrated strips were then resolved on the 12.5% SDS-PAGE in a 
Protean II chamber (Bio-Rad) at 100 V /4°C. 
 
2.3.6 Protein visualization, densitometric analysis and in-gel 
digestion 
 
Gels were silver stained as described by Blum et al 1987 [255]. After fixation, 
gels were washed and sensitized. The gels were then incubated in freshly prepared 
silver nitrate solution (0.2% silver nitrate and 0.026% formaldehyde) for 20 min at 
room temperature followed by 3 times washes of 20 sec each in distilled water. Gels 
were placed in developing solution (6% sodium carbonate, 0.018526% formaldehyde 
and 6% sodium thiosulfate) until standard marker stained completely and adequate 
spots were visualized. Gels were scanned with a gel Cano scan 8400 (Canon, 
Tokyo, Japan). Densitrometric analysis was done by using Delta 2D software version 
3.6 (Decodon GmbH, Gerifswald, Germany) [256]. Spot intensities were first 
normalized and the relative intensity of each spot was calculated by dividing the 
intensity of each spot by the sum of all spots intensities on the corresponding gel. 
Fold change, SD and Student’s t test probability were calculated using Microsoft 
excel software. Spots having at least 1.5 fold expressional changes (p < 0.05) were 
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considered statistically significant. Four independent 2-DE experiments were 
performed.  
 
Differentially regulated protein spots were excised from the silver stained gel 
with a clean scalpel blade followed by in-gel digestion according to the method 
adopted and modified from Shevchenko et al [257]. Briefly, the gel pieces were 
washed twice in 100 mmol/L ammonium bicarbonate/acetonitrile (1:1, v/v) initially for 
10 min and then until all visible dye was removed. The gel pieces were dried using 
vacuum centrifuge (UNIVAPO 150 H; uniEquip, Matinsried, Germany) followed by 
reconstitution in the trypsin digestion solution (10 ng/µL in 100 mmol/L ammonium 
bicarbonate) overnight at 37°C. After incubation the supernatant containing digested 
peptides was transferred to a tube and 50 µL of 0.1% TFA was added followed by 
sonication for 30 min. After sonication, the supernatant was pooled with the previous 
one. Two further extractions were collected in the same way using 0.1% TFA in 30% 
and then 60% ACN. The pooled extracts of peptides were dried in vacuum centrifuge 
and reconstituted in 0.1% formic acid. 
 
2.3.7 Q-TOF LC-MS/MS analysis of protein identification 
 
The reconstituted peptide samples (1 μL) were introduced onto µ-precolumnTM 
cartridge (C18 pepMap; 300 µm x 5 mm; 5 µm particle size) and further separated 
through a C18 pepMap 100 nano- SeriesTM (75 µm x 15 cm; 3 µm particle size) 
analytical column (LC Packings, Germering, Germany) using an CapLC autosampler 
(Waters, Eschborn, Germany). The mobile phase consisted of solution A (0.1% 
formic acid prepared in 5% ACN) and solution B (0.1% formic acid prepared in 95% 
ACN). The sample run time was set to 60 min and the flow rate of the pump to 5 
µL/min. The exponential gradient was initiated at 5 min after loading from 10% to 
95% for the period of 50 min. Tip flow rate of 250 nL/min was achieved through a 
flow splitter. The eluted peptides were injected into a Q-TOF Ultima Global 
(Micromass, Manchester, UK) mass spectrometer equipped with a nanoflow ESI Z-
spray source in positive ion mode. Data was acquired by MassLynx (v 4.0) software 
and peak list (pkl file) was generated from acquired MS/MS raw data using 
ProteinLynx Global Server bioinformatics tool (PLGS; v 2.2; Waters, Manchester, 
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U.K.) under the following settings; Electrospray, centroid 80% with minimum peak 
width 4 channel, noise reduction 10%, Savitzky-Golay, MSMS, medium deisotoping 
with 3% threshold, no noise reduction and no smoothing.  
 
The generated pkl files were searched using the online MASCOT 
(http://www.matrixscience.com) algorithm against the SwissProt data base release 
15.5 (515203 sequence entries, 181334896 elements). The search criteria was set 
as follows: enzyme, trypsin; allowance of up to one missed cleavage peptide; mass 
tolerance ±0.5 Da and MS/MS tolerance ±0.5 Da; modifications of cysteine 
carboamidomethylation and methionine oxidation. Proteins were finally identified on 
the basis of two or more peptides, whose ion scores exceeded the threshold, P < 
0.05, which indicated the 95% confidence level for these matched peptides. To 
ensure accurate identification, protein spots were digested from more than two gels 
and analyzed with MS. Proteins were considered as identified if the threshold was 
exceeded and the protein spot possessed the correct molecular weight and pI value 
of the corresponding spot on 2-DE. 
 
2.3.8 Functional classification 
 
Biological function annotations for all of the identified proteins were done by 
KOGnitor (http://www.ncbi.nlm.nih.gov/COG/grace/kognitor.html) [258]. 
 
2.3.9 Western blotting 
 
Proteins were separated on 12.5% SDS-PAGE and blotted onto PVDF 
membrane (ImmobilonP, Millipore) using semidry Trans-Blot® SD cell system (Bio-
Rad, Munich, Germany) for 30 min at 15 V in a blotting buffer (192 mmol/L glycine, 
20% methanol, 25 mmol/L Tris [pH 8.3]). The membranes were blocked with 5% 
(w/v) skimmed milk repared in TBS-T buffer (50 mmol/L Tris–HCl [pH 7.5], 200 
mmol/L NaCl, 0.05% Tween 20) for 1 hr at room temperature and washed twice with 
TBS-T buffer. The membranes were incubated with 1:1000 mouse anti Prdx1 
antibody (Abcam, Cambridge, MA), 1:1000 rabbit anti MLC2 (Cell Signaling 
Technology, Inc., Danvers, MA) and 1:1000 mouse anti beta tubulin (Biovender, 
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Czech Republic) overnight at 4°C, followed by washes with TBS-T buffer. 
Membranes were further incubated with appropriate HRP-conjugated secondary 
antibodies for 1 hr at room temperature. The signals on the blots were detected by 
using ECL system (GE Healthcare) according to manufacturer’s instructions. Signal 
intensities from each Western blot were quantified by using Lab Image software, 
version 2.71 (Leipzig, Germany). β tubulin was used as a loading control and at least 
four independent experiments were performed. 
2.3.10 RNA isolation and cDNA synthesis 
 
RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer’s recommendations. Briefly, cells were scraped, washed 
and then homogenized in Trizol reagent. RNA was separated by 
chloroform/isopropanol precipitation method. The concentration of RNA was 
determined by the GeneQuant II RNA/DNA calculator (Pharmacia Biotech, Freiburg, 
Germany). The RNA quality was verified at OD260/OD280 nm ratios and subsequent 
electrophoretically on 1% agarose gels using ethidium bromide staining. The cDNAs 
were synthesized from 2 µg total RNA in a 30 µL reaction mix containing 1X reverse 
transcriptase (RT) PCR buffer (10 mmol/L Tris-HCL [pH 8.3], 15 mmol/L KCl, 0.6 
mmol/L MgCl2), 0.5 mmol/L of dNTPs mix, 1 U/µL RNase inhibitor and 13.3 U/µL M-
MLV RT enzyme. The RT reaction was performed in a thermocycler (Biometra, 
Goettingen, Germany) at 42°C for 1 hr. cDNA was stored at -70°C until use. 
 
2.3.11 Real-time PCR 
 
Relative quantitative PCR were carried out using the LightCycler instrument 
(Roche Diagnostic Systems, NJ, USA). The primers for the human Prdx1 (forward 5′-
TGGGGTCTTAAAGGCTGATG-3′ and reverse 5′-TCCCCATGTTTGTCAGTGAA -3′), 
human MLC2 (forward 5′- CAGGAGTTCAAAGAGGCCTTCAAC -3′ and reverse 5′- 
CTGTACAGCTCATCCACTTCCTCA -3′) and elongation factor 2 (forward 5′-
GACATCACCAAGGGTGTGCAG-3′ and reverse 5′-GCGGTCAGCACACTGGCATA-
3) were designed by the Primer3 software (http://frodo.wi.mit.edu) [259]. The total 
volume of 20 µL PCR contained 1 µL of cDNA solution, 2 µL of 10X PCR buffer 
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(Invitrogen), 2 µL Syber green, 1 µL BSA, 1 µL DMSO, 0.25 µL of each primer 
(Eurofins MWG-Biotech, Ebersberg, Germany), 2.0 mmol/L MgCl2, 0.2 mmol/L 
dNTPs mix and 0.15 U/µL PAN Script DNA polymerase (PAN Biotech, Aidenbach, 
Germany). The amplification conditions for Prdx1 and MLC2 were: initial denaturation 
30 sec at 95°C and repeated cycles of denaturation (95°C for 1 sec), primer 
annealing (55°C for 5 sec), elongation (72°C for 10 sec), and fluorescence reading at 
82 °C. For elongation factor 2 (EF-2) PCR conditions were similar to Prdx1 except for 
primer fluorescence reading which was measured at 88°C.  
 
The relative expression of Prdx1 and MLC2 mRNA in the treated samples 
was determined as a fold increase compared with control samples using the 
comparative threshold cycle (CT) method 2
-ΔΔ C
T(ΔΔCT = ΔC target genes − ΔC 
reference gene) [260]. EF-2 was used as the internal control gene. Experiments were 
performed four times. Statistical difference (p value) in mRNA expression level 
between MPA and DMSO samples were calculated using the Mann-Whitney U test. 
The PCR product was run on a 1% ethidium bromide-agarose gel to confirm the 
presence of desired specific amplified product.  
 
2.3.12 Apoptosis assay 
 
The caspase 3 activity was measured using CaspACETM Assay kit (Promega 
Corporation, WI, USA) according to the manufacturer’s protocol. Cells were treated 
with DMSO and MPA for 72 hr, harvested and briefly suspended in lysis buffer. 
Proteins were extracted and quantified by Bradford method [252]. Briefly, 70 μg of 
protein lysate were mixed with reaction mixtures containing colorimetric substrate 
peptides specific for caspase 3 (DEVD-pNA) and then incubated at room 
temperature for overnight. The absorbance of the cleaved p-nitroanilide from the 
substrate DEVD-pNA was measured at 405 nm using EL808 microplate reader (Bio-
Tek instruments, VT, USA). Five independent experiments were performed.  
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2.4 Results 
 
In the present study the alteration in the cellular proteome by the MPA treatment 
was investigated using HEK-293 as cell culture model. Incubation of HEK-293 cells 
with MPA followed a dose dependent inhibition of cell proliferation (Figure 2.1). The 
IC50 concentration (7.5 µmol/L or 2.4 mg/L) of MPA was selected as standard dose 
for further analysis, which is within the therapeutic range (0.3 to 3.4 mg/L) [261]. 
Cells were treated with MPA and DMSO (as vehicle) for 3 days, and total cell lysates 
were prepared. Total protein extracts of MPA and DMSO treated cells were 
separated by 2-DE using pH 3-10 linear IPG strips and visualized by silver stain. The 
protein spots which showed ≥±1.5 fold change (p < 0.05 using Student’s t test) as 
compared to DMSO treated controls were considered as differentially expressed 
proteins. Statistical analysis showed that a total of 12 proteins exhibited significantly 
altered expression due to MPA treatment (Table 2.1). The altered expression pattern 
of the HEK-293 proteins by MPA is shown in Figure 2.2.  
 
Among 12 regulated proteins spot under MPA treatment, 7 proteins were 
significantly up-regulated and 5 proteins showed down-regulated expression. The up-
regulated spots under MPA treatment were identified as complement component 1Q 
subcomponent binding protein (C1q), electron transfer flavoprotein subunit beta, 
cytochrome b-c1 complex subunit, thioredoxin domain-containing protein 12, myosin 
regulatory light chain 2 (MLC2), peroxiredoxin1 (Prdx1) and profilin 1. Five proteins, 
which showed down-regulated expression, were identified as protein SET, stathmin, 
40S ribosomal protein S12, histone H2B type 1-A, and histone H2B type 1-C/E/F/G/I. 
A bar diagram, showing relative abundance (% Vol), SD and statistical significance of 
all the significantly regulated protein is provided as figure 5.1. Figure 2.2 shows an 
exemplary gel of DMSO (vehicle) and MPA with marked regulated proteins. The 
extent of regulation in protein expression with predicted and actual pI, as well as 
molecular masses with their SwissProt accession numbers are provided in Table 2.1 
and MS/MS spectral information is provided in the figure 5.2.  
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Table 2.1. Differentially regulated proteins by MPA in HEK-293 cells identified 
by mass spectrometry  
Spot No Acc Mt/Mo(kDa) Score pIt/ pIo Pep Protein name 
Function 
By KOGnitor NCBI 
 
Expression 
change 
(in folds) 
 
6 Q01105 33.4/37.0 154 
 
4.23/4.14 
 
3 Protein SET 
Replication, 
recombination and repair 
1.86*↓ 
9 
 
Q07021 
 
31.3/31.0 
 
141 
 
4.74/4.5 3 
Complement 
component 1 Q 
subcomponent-
binding protein, 
mitochondrial 
Defense mechanisms 1.58*↑ 
14 P38117 27.8/25.5 181 
 
8.24/9.18 
 
6 
 
Electron transfer 
flavoprotein subunit 
beta 
Energy production and 
conversion 
1.54*↑ 
15 
 
P47985 
 
29.6/25.0 112 8.51/7.081 6 
 
Cytochrome b-c1 
complex subunit 
Rieske, mitochondrial 
 
Energy production and 
conversion 
3.71**↑ 
18 Q06830 22.0/21.0 64 8. 27/8.14 2 Peroxiredoxin-1 
Posttranslational 
modification, protein 
turnover, chaperones 
1.71**↑ 
22 P16949 17.2/15.8 56 
 
5.76/6.32 
 
3 Stathmin 
General function 
prediction only 
1.50**↓ 
23 O95881 19.1/16.0 123 5.24/5.89 4 
Thioredoxin domain-
containing protein 12 
 
Cytoskeleton 
 
1.95*↑ 
24 O14950 19.7/16.0 195 4.71/5.32 4 
Myosin regulatory light 
chain MRLC2 
Cytoskeleton 3.41*↑ 
27 Q96A08 14.1/14.5 51 10.31/7.0 2 Histone H2B type 1-A 
Chromatin structure and 
dynamics 
1.90*↓ 
28 P62807 13.8/14.2 250 10.31/6.51 9 
Histone H2B type 1-
C/E/F/G/I 
Chromatin structure and 
dynamics 
1.58*↓ 
31 P25398 14.5/13.0 89 6.81/7.10 3 
40S ribosomal protein 
S12 
 
Translation, ribosomal 
structure and biogenesis 
2.44*↓ 
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P07737 
 
15.0/13.5 
 
142 
 
8.44/9.07 
 
6 
 
Profilin-1 
 
Cytoskeleton 
 
1.51**↑ 
Acc: Accession number; Mt: theoretical molecular mass; Mo: observed molecular mass; pIt: theoretical 
isoelectric point; pIo: observed isoelectric point; pep: number of peptides sequenced for identification; 
Score: Peptide mass fingerprint probability score as defined by Mascot (www.matrixscience.com). 
Individual ions score >42 indicate identity or extensive homology (p < 0.05); ↓: down-regulated; ↑ up-
regulated; *p < 0.05, **p < 0.005. Molecular function determined from the online protein reference 
database KOGnitor NCBI. (http://www.ncbi.nlm.nih.gov/COG/grace/kognitor.html). 
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Figure 2.1: Inhibition of HEK-293 cells proliferation by MPA treatment.  
The cell proliferation was determined after 72 hr of treatment with different doses of MPA (0–100 
µmol/L) using BrdU colorimetric based method. Results are shown as percentage of control (DMSO 
treated) and represent four independent experiments. 
 
 
Figure 2.2: Differential protein expression after incubation of HEK-293 cells with MPA.  
Total protein lysate from DMSO and MPA treated cells was separated by 2-D gel electrophoresis and 
silver stained. Encircled differentially regulated proteins spots were identified using Q-TOF MS/MS 
analysis. The figure shows exemplary 2-DE gels of DMSO and MPA treated HEK-293 cells.   
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Figure 2.3: Functional classification of regulated proteins.   
Biological functions were assigned using online KOGnitor NCBI. 
(http://www.ncbi.nlm.nih.gov/COG/grace/kognitor.html) software.   
 
Functional classification of differentially regulated proteins was done using 
KOGnitor, an online biological function annotation tool [258]. The proteins altered by 
MPA treatment belong to various categories i.e., cytoskeleton (26%), chromatin 
structure/dynamics and energy production/conversion (17% each) (Figure 2.3). Gels 
spot diagram of two selected protein spots (MLC2 and Prdx1) in 4 biological 
replicates are shown in Figure 2.4a 
 
To validate the 2-DE results, the expression of MLC2 and Prdx1 were confirmed 
by Western blotting and real time PCR analysis. Expression of Prdx1 and MLC2 were 
up-regulated at both transcriptional (Figure 2.4b) and protein level (Figure 2.4c). 
Specifically, MPA increased MLC2 protein (Mean fold: +1.78, p < 0.005, n = 4, 
Western blotting) and mRNA expression (Mean fold: +2.25, p < 0.05, n = 4, real time 
PCR). Prdx1 expression was also up-regulated, both at protein level (Mean fold: 
+2.73, p < 0.005, n = 4) and mRNA level (Mean fold: +1.93, p < 0.05, n = 4). To 
check whether over-expression of MLC2 following MPA treatment is only HEK-293 
cells specific, we determined MLC2 expression in total protein lysate prepared from 
kidney of MMF (pro-drug of MPA) treated rats (Figure 2.5a) and MPA treated HT-29 
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cells (Figure 2.5b). MLC2 expression was increased both in kidney total protein 
lysate and HT-29 cells by (Mean fold: +2.57, p < 0.005, n = 4) and (Mean fold: +1.95, 
p < 0.005, n = 4) respectively.  
 
 
 
 
 
 
 
 
 
 
Figure 2.4: Differential expression of Prdx1 and MLC2 by MPA treatment.  
(a) Selected areas in the silver stained gels showing differential expression of Prdx1 and MLC2. Delta 
2D software was used for densitrometric analysis. The quantification of the level of expression (% 
volume) in MPA treated cells and control cells (DMSO) is illustrated as a bar chart with the mean and 
SD of four separate experiments (*p < 0.05). (b) Expression patterns of Prdx1 and MLC2 genes 
determined by real-time PCR. The relative expression of Prdx1 and MLC2 mRNA in the treated 
samples was determined as a fold change compared with control samples using the comparative 
threshold cycle (CT) method (2
-ΔΔC
T) as described in materials and methods part. Results shown are 
representative of four independent experiments. EF-2 was used to normalize the values. The boxes 
represent range in variation statistics and the lines across the boxes represent the medians and the 
whiskers extend to the highest and lowest values. Significance was calculated using the Mann-
Whitney-U test (*p < 0.05) (c) Effect of MPA treatment on Prdx1 and MLC2 protein expression. Protein 
extracts from MPA and DMSO treated cells were Western blotted using specific antibodies against 
Prdx1 and MLC2. Densitometric analysis was done using Lab image version 2.71 software. β tubulin 
signal was used to control the equal protein load. The experiments were repeated four times and error 
bars represent ± SD (**p < 0.005). 
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Figure 2.5: Expression of MLC2 in MMF treated rat kidney lysate and HT-29 cells.  
Protein lysate was prepared and immunoblotted for MLC2 as described in method section. β tubulin 
was used to show equal protein load. Lab image software was used for quantification of protein bands. 
Four independent experiments were performed and results presented as mean ± SD (**p < 0.005). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Measurement of MPA induced caspase-3 activity.  
Cells were treated with MPA and DMSO for 72 hr. Protein extracts from each was measured for 
caspase-3 activity. Five independent experiments were performed and results presented as mean 
absorbance ± SD (**p < 0.005). 
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To demonstrate the effect of MPA on cell apoptosis, caspase-3 activity 
(apoptosis marker) was determined using a commercially available colorimetric 
assay. There was a significant difference in caspase-3 activity between MPA and 
DMSO treatment groups. MPA increased mean absorbance by 2 fold (p < 0.005, 
n = 5) as compared to DMSO treated cells. The results from caspase-3 assay 
revealed that MPA treated cells exhibit more apoptosis than cells treated with DMSO 
alone (Figure 2.6). 
 
2.5 Discussion 
 
We have used a 2-DE and mass spectrometric based proteomics approach to 
develop a better understanding of the influence of MPA therapeutic dose on the 
proteome in HEK-293 cells. HEK-293 cells are widely used cell culture model to 
study the mechanisms of drug action, investigating drug targets and molecular 
aspects of xenobiotic toxicity [262-264]. The regulated proteins are found to be 
involved in diverse functions including apoptosis and cell signaling mechanism. 
Apoptosis assay showed that MPA has a pro-apoptotic role in HEK-293 cell line, a 
property which makes it a drug with potential anti-tumor activities. MLC2 is an 
important myosin regulatory subunit, which regulates smooth muscle and nonmuscle 
cells contractile activity [265]. MLC2 displayed an increased expression by MPA 
treatment. It is already reported that MPA influences the cellular cytoskeletal 
architecture via modulating mesangial actin reorganization by activating actin 
polymerization and inhibiting actin-depolymerization [266,267]. Phosphorylation of 
MLC2 causes significant changes in the physiological dynamics of actin cytoskeleton, 
leading to barrier defects in intestine [184], heart [268] and lungs [269]. However, it 
remains unclear if such cytoskeleton reorganization in different organs may lead to a 
completely different outcome, for example in intestine, diarrhoea is associated with 
MPA therapy in some patients [251]. In the present study, we observed that MLC2 
over-expression is not limited to a specific cell type (i.e. HEK-293) but was 
reproducible in MMF treated rat kidney and in MPA treated HT-29 cells protein 
lysates. 
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We observed an increase Prdx1 expression by MPA treatment, both at gene 
and protein level. Prdx1 is a cytoplasmic stress-inducible anti-oxidant enzyme and a 
major member of peroxiredoxin family [270]. Cells deficient in Prdx1 have increased 
sensitivity to oxidative DNA damage [271]. Prdx1 along with its anti-oxidant activity 
also possesses anti-inflammatory and anti-atherogenic effects [272]. Oxidative stress 
contributes to the pathophysiology of diverse clinical conditions, including ischemia-
reperfusion mediated post transplantation graft injuries [273]. Prdx1 expression was 
also reported to be up-regulated in human gingival fibroblasts by cyclosporine A 
(another commonly used immunosuppressive drug) treatment [274]. MPA has 
previously been reported to diminish oxidative injuries and induce anti-oxidant effects 
by preventing the production of reactive oxygen species [249]. Furthermore, MPA 
exerts lesser oxidative stress in renal transplant patients, as compared to everolimus, 
cyclosporine and other calcineurin inhibitors [275,276].  
 
Prdx1 contribute to the inhibition of tumorigenesis through PTEN/Akt pathway 
[277] and its lower expression in the tumor indicated high tumor proliferation, 
increased metastasis and could be used as cancer biomarker [278]. Prdx1 is also 
involved in ageing process as Prdx1-deficient mice have a shortened lifespan and 
other malignancies [271]. Anti-tumor drugs like histone deacetylase inhibitors 
(HDACIs) activate Prdx1, a tumor suppressor, which leads to apoptosis [279]. 
Previously it was observed that MPA also inhibit histone deacetylases (HDACs) [21]. 
A further investigation is needed to gain a deeper insight into the Prdx1 regulation by 
MPA through HDACs inhibition interaction with Prdx1 and its role in anti-tumor 
activities. 
 
Profilin 1, another cytoskeletal protein was up-regulated by MPA treatment. 
Profilins are widely distributed actin binding proteins [280], involved in actin filament 
dynamics and several signaling pathways [281]. Profilin 1 over-expression has been 
reported to cause cell proliferation inhibition, apoptosis induction and tumor 
suppression [282]. Whether MPA via profilin over-expression exerts extended anti-
proliferative or anti-tumor activities requires further investigation. Stathmin was down 
regulated by MPA. Stathmin is a 19 kDa cytoplasmic protein, which plays an 
important role in the regulation of the microtubule cytoskeleton. Stathmin regulates 
microtubule turnover by promoting microtubules depolymerization and hydrolyze 
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guanosine triphosphate (GTP) from terminal tubulin, preventing polymerization of 
tubulin heterodimers [283]. Previously, our group demonstrated that AcMPAG alters 
tubulin polymerization in a concentration-dependent manner [284]. Furthermore, 
stathmin repression stabilizes microtubules, inhibits angiogenesis [285] and suppress 
tumors [286].  
 
Thioredoxin domain-containing protein 12, also known as endoplasmic reticulum 
resident protein 18 (ERp18) is ubiquitous in mammalian cells and acts as a disulfide 
isomerase in the endoplasmic reticulum (ER). It provides defense against oxidative 
stress, refolds disulfide-containing proteins, and regulates transcription factors [287]. 
ERp18 expressional up-regulation might cause cell adoptivity in response to MPA 
induced ER stress. SET protein was down-expressed by MPA. SET, a major cellular 
serine threonine phosphatase is a potent inhibitor of protein phosphatase 2A (PP2A) 
activity [288] and a negative regulator of histone acetylation [289], thus involved in 
cell growth and signaling cascades [290]. PP2A expression induced by down-
regulation of SET leads to the apoptosis and growth suppression [291],  
 
MPA triggers nuclear stress and causes disruption of the nucleus, leading to the 
activation of p53, which may initiate cell cycle arrest and apoptosis [292]. In the 
present study histone H2B was down-regulated by MPA treatment, which is a major 
component of eukaryotic nucleosome core. Post translational modification such as 
methylation, acetylation, phosphorylation and ubiquitination of histone proteins alter 
transcription, DNA replication, and DNA repair [293,294]. Previous data showed that 
MPA mediated down-regulation of HDAC2 which might relate with potential 
epigenetic regulations [21]. The microrarray analysis of mononuclear cells treated 
with AcMPAG (a metabolite of MPA) showed down-regulation of histones in a 
previous study by our group [295].  
 
MPA affects ribosomal machinery by decreasing intracellular guanine nucleotide 
level, depending on dosage and cell type, resulting in global reduction of RNA 
synthesis [292]. Other studies suggested that guanine nucleotide depletion by 
IMPDH leads to a decrease in pre-ribosomal RNA synthesis, nuclear disruption, and 
p53 activation [296]. Disorganization of nuclear and ribosomal biogenesis is 
suggested to be an effective therapeutic target in cancers [297]. We observed a 
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down-regulation of 40S ribosomal protein S12 by MPA, which might be due to the 
altered ribosome biogenesis. The proapoptotic stimuli including chemotherapeutic 
agents induced a dose-dependent increase in the expression of the cytochrome c 
proteins [298].  
 
In the present study we also observed up-regulation of cytochrome b-c I 
complex by MPA which suggests a possible role of MPA in the regulation of energy 
metabolism. Complement component 1 Q subcomponent-binding protein (C1q), a 
component of complement system involved in the clearance of apoptotic cells was 
up-regulated by MPA. C1q binds to surface blebs of apoptotic cells, which follows 
subsequent phagocytosis [299]. C1q deficiency leads to a significant decline in the 
clearance of apoptotic cells in both C1q- and C4-deficient mice, causing 
glomerulonephritis [300]. MPA causes cellular apoptosis and cells might utilize C1q 
over-expression to clear the apoptotic cells.  
 
2.6 Conclusion  
 
This investigation identifies proteins related to diverse cellular functions which 
altered their expression by MPA treatment; many of which are reported for the first 
time in this context. The expression of Prdx1 (involved in apoptosis) and MLC2 
(protein important for epithelial barrier integrity) were observed to be regulated at 
RNA and protein level. Further investigations of the regulated proteins will provide 
new insights into the cellular pathways influenced by MPA therapy and could help in 
more rational use of MPA in transplantation medicine. 
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3.1 Abstract 
 
Gastrointestinal toxicity is a common adverse effect of mycophenolic acid (MPA) 
treatment in solid organ transplantation patients, through poorly understood 
mechanisms. Phosphorylation of myosin light chain 2 (MLC2) is associated with 
epithelial tight junction modulation which leads to defective epithelial barrier function, 
and has been implicated in gastrointestinal diseases. The aim of this study was to 
investigate whether MPA could induce epithelial barrier permeability via MLC2 
regulation. Human colonic cells (Caco-2) monolayers were exposed to therapeutic 
concentrations of MPA, and MLC2 and myosin light chain kinase (MLCK) expression 
were analysed using PCR and immunoblotting. Permeability was assessed by 
measuring transepithelial resistance (TER) and the flux of paracellular permeability 
marker FITC-dextran across the epithelial monolayers. MPA increased the 
expression of both MLC2 and MLCK at both the transcriptional and translational 
levels. In addition, the amount of phosphorylated MLC2 was increased after MPA 
treatment. Confocal immunofluorescence analysis showed disrupted distribution of 
tight junction proteins (ZO-1 and occludin) after MPA treatment. This MPA mediated 
tight junction disruption was not due to apoptosis or cell death. AcMPAG, a reactive 
metabolite of MPA, also showed similar effects on TER and TJ proteins expression 
and distribution. Additionally ML-7, a specific inhibitor of MLCK was able to reverse 
both the MPA mediated decrease in TER and the increase in FITC-dextran influx, 
suggesting a modulating role of MPA on intestinal epithelial barrier permeability via 
MLCK activity. These results suggest that MPA induced alterations in MLC 
phosphorylation may have a role in the patho-physiology of intestinal epithelial barrier 
disruption and may be responsible for the adverse effects of MPA on the intestine. 
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3.2 Introduction 
 
The tight junctions (TJs) are intercellular, multifunctional complexes present in 
the epithelial and endothelial cells which form the paracellular diffusion barrier 
[97,100]. This barrier contributes to the regulation of epithelial permeability and 
intramembrane diffusion of ions and solutes through the paracellular space [301-
303]. TJs are comprised of transmembrane (occludin, claudins and junctional 
adhesion molecules) and peripheral membrane proteins (zonula occludins [ZO-1], 
membrane-associated guanylate kinase, and the Ras-related protein Rab13). These 
proteins interact with each other to form a complex protein  network [304]. Various 
intestinal and non-intestinal disorders including inflammatory bowel disease, celiac 
disease, and diarrhoeal infections are characterized by barrier dysfunction which is 
thought to play a crucial role in their pathogenesis [303].   
 
Mycophenolic acid (MPA) is the active agent in  the two currently commercially 
available formulations: the MPA ester mycophenolate mofetil (MMF) and the enteric-
coated salt mycophenolate sodium (EC-MS) [7]. After oral ingestion, MPA is liberated 
in the gastrointestinal tract, absorbed and metabolized in the liver to form MPA 
glucuronide (MPAG) and two other metabolites, 7-O-glucoside and acyl glucuronide  
(AcMPAG). AcMPAG is pharmacologically active and believed to be responsible for 
some MPA associated GI tract adverse effects [30]. MPA is an immunosuppressant 
which is frequently used for the prevention of acute transplant rejection. MPA  is also 
used for the treatment of non-transplant, autoimmune, renal, rheumatological, 
gastrointestinal, ophthalmological, dermatological and neurological diseases [250].  
 
Several immunosuppressive drugs including MPA used in solid organ 
transplantation lead  to diarrhoea [305]. Various possible aetiologies of this diarrhoea 
have been described including infectious agents, drug reactions, metabolic 
alterations, and surgical complications. MPA has been claimed to account  for 50% of 
all drug induced post-transplantation diarrhoea [306], while 20% of total MPA 
complications involve the GI  tract [307,308]. GI symptoms similar to those seen with 
Crohn’s disease and enterocolitis are also observed in patients receiving MPA 
therapy [65,309-312]. The underlying mechanisms of MPA  induced GI toxicity 
remain unclear; however, several hypotheses  exist  including direct toxicity  as a 
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result of its anti-proliferative effects, myelosuppression induced opportunistic 
infections, variations in local immune response, and AcMPAG adduct  toxicity 
[36,251,305]. 
 
Several GI associated abnormalities, including inflammatory bowel disease 
(Crohn's disease and ulcerative colitis), and Graft verses host disease are 
characterized by epithelial barrier defects which contribute to increased intestinal 
permeability [313]. The effects of MPA or its metabolites on cell junction biophysical 
properties including paracellular permeability, and the regulation of TJ proteins, 
especially in relation to intestinal barrier defects, have not been well studied.  Studies 
were conducted to explore the molecular effects of MPA and its active AcMPAG 
metabolite on gut integrity via possible effects on TJs. We used Caco-2 cell 
monolayers as in vitro model of intestinal epithelia [314] and incubated them with 
therapeutic concentrations (3.1 mg/L, or 10 µmol/L) of MPA and (10 µmol/L) 
AcMPAG. Trans-epithelial resistance (TER) measurements, paracellular influx 
assays, immunoblotting and immunofluorescence analyses were then conducted to 
evaluate integrity of the TJs complex. We hypothesized that MPA may modulate the 
TJs by altering expression and distribution of crucial TJs proteins. 
  
3.3 Materials and methods 
 
3.3.1 Reagents 
 
Reagents (and their sources) included: agarose (Gibco BRL, Paisley, UK), 
Magnesium chloride (MgCl2), M-MLV RT enzyme and 5X buffer (Invitrogen, 
Karlsruhe, Germany), deoxynucleotide triphosphate (dNTP) (Roche, Mannheim, 
Germany), Ribonuclease (RNAase) inhibitor (Promega, Mannheim, Germany),  MPA, 
fluorescein isocynate-dextran 4 KDa (FD4), 1-5-Iodonaphthalene-1-sulfonyl)-1H-
hexahydro-1,4-diazepine hydrochloride (ML-7) and cytochalasin (CD) (Sigma-Aldrich, 
Mannheim, Germany) and PCR primers (Eurofins, Ebersberg, Germany). AcMPAG 
was a kind gift from Roche (Roche, Mannheim, Germany). 
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3.3.2 Cell culture 
 
The human colon adenocarcinoma cell line (Caco-2) was purchased from 
DSMZ (German collection of microorganisms and cell cultures, Braunschweig, 
Germany). Tissue culture media ingredients were obtained from PAA Laboratories 
(Pasching, Austria). Cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (4.5 g/L glucose) supplemented with 10% heat-inactivated fetal calf serum, 
2 mmol/L glutamine, 50 IU/mL penicillin, 50 mg/mL streptomycin and non-essential 
amino acid supplement (1% v/v) under conditions of 37°C, 5% CO2 and 90% relative 
humidity. The Caco-2 cells were allowed to grow for 21 days of post-confluence to 
form differentiated and polarised monolayer growth [315]. The culture medium was 
changed every second day. 
 
3.3.3 Lactate dehydrogenase (LDH) measurement 
 
 LDH measurements were performed using a commercially available LDH 
measurement kit (Roche, Mannheim, Germany) according to the manufacturer’s 
instructions. This assay is based on the principle that LDH catalyzes the conversion 
of NADH (substrate) to NAD and the rate of this conversion is directly proportional to 
LDH activity. Briefly, cells were incubated in DMSO, 10 µmol/L MPA or 10 µmol/L 
AcMPAG for 72 hr. Following incubation, supernatant medium was collected, 
centrifuged for 5 min at 15,700 x g at 4°C and LDH was measured photometrically 
using a Hitachi analyzer (Roche, Mannheim, Germany). The experiments were 
repeated at least four times and values were represented as mean IU/L ± SEM.  
 
3.3.4 Determination of caspase 3 activity 
 
Cell were treated with DMSO, 10 µmol/L MPA or 10 µmol/L AcMPAG for 72 hr 
and the caspase specific activity was measured using CaspACETM Assay kits 
(Promega, WI, USA) as previously described [316]. Briefly, cell proteins (70 µg) were 
mixed with reaction mixtures containing the colorimetric substrate Ac-DEVD-p-
nitroanaline (Ac-DEVD-pNA). The pNA released from Ac-DEVD-pNA due to caspase 
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activity was measured at a wavelength of 405 nm using a EL808 microplate reader 
(Bio-Tek instruments, VT, USA). Caspase 3 specific activity (CSA) in the cell extract 
was measured using the standard formula (CSA = pmol pNA liberated per hour/ μg 
protein). Five independent experiments were performed and results were expressed 
as mean pmol pNA liberated per hour/ μg protein. 
 
3.3.5 Determination of trans-epithelial resistance (TER) 
  
TER was measured as previously described [317]. Briefly, cells were seeded 
on polyester transwell inserts (6.5 mm diameter, 0.4 µm pore size, 0.33 cm2 growth 
area, Corning Costar Corporation, NY, USA) at 2.0 x 105 cells/well and grown for 21 
days post-confluence. Cells were treated with DMSO, 10 µmol/L MPA, 10 µmol/L 
AcMPAG or CD (10 µmol/L) for 72 hr or pre-treated with ML-7 (10µmol/L) for 1 hr 
followed by 72 hr treatment of MPA (10 µmol/L) after cells developed into a 
differentiated and polarised monolayer. TER was measured using an EVOM 
voltohmmeter with a STX2 electrode (WPI, FL, USA). For epithelial resistance 
measurements, both the apical and basolateral sides of the epithelia were bathed in 
cell culture medium. Resistance (TER) = [RC-RE] X A; where RC is resistance of the 
cells (Ω); RE is resistance of the blank (Ω); and A is surface area of the membrane 
insert (cm2). TER was calculated as Ω.cm2 for at least four consecutive 
measurements.  
 
3.3.6 FITC-dextran paracellular permeability 
 
Epithelial permeability was assessed using a previously reported method 
[318,319]. Briefly, Caco-2 cells were grown into monolayers and treated as described 
above.  Following treatment, cells were rinsed with PBS and incubated in Hank’s 
balanced salt solution containing 1mg/mL FITC-dextran 4 kD (FD4) solution for 2 hr. 
Permeability marker flux was assessed by taking 100 µL from the basolateral 
chamber. Fluorescent signal was measured using a Lambda fluoro 320 fluorescence 
plate reader (MWG Biotech, Ebersberg, Germany) using 492 nm excitation and 520 
nm emission filters. FD4 concentrations were determined using standard curves 
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generated by serial dilution of FD4. Fluxes were calculated using the apparent 
permeability coefficient (Papp) equation: Papp = ΔCA/Δt)*VA]/A*CL, where Papp is the 
apparent permeability (cm/s), ΔCA is the change of FD4 concentration, A is the 
surface area of the membrane (cm2), Δt is the change of time, VA is the volume of the 
abluminal medium, and CL is the initial concentration in the luminal chamber. 
 
3.3.7 RNA isolation, cDNA synthesis and real-time PCR 
 
Total cellular RNA was extracted using the acid guanidinium-phenol-
chloroform method (Trizol reagent; Invitrogen, CA) according to manufacturer’s 
recommendations. Briefly, Caco-2 monolayers were scraped into Trizol reagent, 
homogenized, and RNA was extracted using chloroform/isopropanol precipitation. 
The precipitated RNA was dissolved in sterile water and stored at -80°C until 
analysis. RNA concentration was determined with the GeneQuant II RNA/DNA 
calculator (Pharmacia Biotech, Freiburg, Germany) and quality was verified by 
OD260/OD280 nm ratios and subsequent electrophoresis in 1.5% agarose gels using 
ethidium bromide staining. cDNA was synthesized from 2 µg total RNA in a 30 µL 
reaction mix containing 1x RT-PCR buffer (10 mmol/L Tris-HCL [pH 8.3], 15 mmol/L 
KCl, 0.6 mmol/L MgCl2), 0.5 µmol/L of each dNTP, 1 U/µL RNase inhibitor and 13.3 
U/µL M-MLV RT enzyme. The RT reactions were performed in a thermocycler 
(Biometra, Goettingen, Germany) at 75°C for 5 min, and then 42°C for 1 hr. cDNA 
was stored at -80°C until use. 
Primers for real time PCR were selected using the online Primer 3 software  [320]. 
The primers used in this study were as follows: MLC2 (forward 5′-
CAGGAGTTCAAAGAGGCCTTCAAC-3′, reverse 5′- 
CTGTACAGCTCATCCACTTCCTCA-3′); MLCK (forward 5′-
CAACAGGGTCACCAACCAGC-3′, reverse 5′-GCCTTGCAGGTGTACTTGGC-3′); 
ROCK (forward 5′-GTGAAGGTGATTGGTAGAGGTGC-3′, reverse 5′- 
CCACCAGGCATGTATTCCATCAC-3′) and elongation factor 2 (forward 5′- 
GACATCACCAAGGGTGTGCAG-3′, reverse 5′-GCGGTCAGCACACTGGCATA-3). 
Relative quantitative PCR was carried out using the LightCycler instrument (Roche, 
Manheim, Germany). The total PCR volume of 20 µL contained 1 µL of cDNA 
solution, 2 µL of 10X PCR buffer (Invitrogen, Darmstadt, Germany), 2 µL syber 
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green, 1 µL BSA, 1 µL DMSO, 0.25 µL of each primer (Eurofins MWG-Biotech AG, 
Ebersberg, Germany), 2.0 mmol/L MgCl2, 0.2 mmol/L of each dNTP, and 0.15 U/µL 
PAN Script DNA polymerase (PAN Biotech, Aidenbach, Germany). Amplification 
conditions were set to: MLC2 (initial denaturation 30 sec at 95°C, repeated cycles of 
denaturation at 95°C, for 1 sec, primer annealing at 55°C for 5 sec, elongation at 
72°C for 10 sec, and fluorescence reading at 82°C), MLCK (initial denaturation for 30 
sec at 95°C and repeated cycles of denaturation at 95°C for 1 sec, primer annealing 
at 60°C for 5 sec, elongation at 72°C for 10 sec, and fluorescence reading at 82°C). 
ROCK (initial denaturation for 30 sec at 95°C and repeated cycles of denaturation at 
95°C for 1 sec, primer annealing at 60°C for 5 sec, elongation at 72°C for 10 sec, and 
fluorescence reading at 80°C), elongation factor 2 (EF-2) (initial denaturation for 30 
sec at 95°C, repeated cycles of denaturation at 95°C, for 1 sec, primer annealing 
(55°C, 5 sec), elongation (72°C, 10 sec), and fluorescence reading at 88°C). For 
each sample, real-time PCR reactions were performed in quadruplicate. RNA relative 
expression was calculated as fold change using the comparative threshold cycle (CT) 
method (2-ΔΔ CT) [260] with EF-2 used as the internal control gene. The relative 
expression of mRNA in the treated samples was determined as a fold increase 
compared with control samples. The PCR product was run on 1.5% agarose gel 
electrophoresis to confirm the specificity of the amplified product. 
 
3.3.8 Immunoblotting 
 
Protein lysates were separated by SDS-PAGE and blotted onto PVDF 
(Immobilon, Millipore, MA, USA) using the Trans-Blot SD cell system (Bio-rad, 
Munich, Germany) for 30 min at 15 V in a blotting buffer (192 mmol/L glycine, 20% 
methanol, and 25 mmol/L tris [pH 8.3]). The membranes were blocked with 5% (w/v) 
milk in TBS-T buffer (50 mmol/L TrisHCl [pH 7.5], 200 mmol/L NaCl, 0.05% Tween 
20) for 1 hr at room temperature followed by washing twice in TBS-T for 5 min.  The 
membranes were  incubated with a 1: 500 dilution of a mouse monoclonal anti-MLC 
antibody (Sigma, Mannheim , Germany), 1: 10000 dilution of mouse monoclonal anti-
MLCK antibody (Sigma, Mannheim , Germany), 1: 1000 rabbit anti-phospho MLC 
antibody (Cell Signaling, Beverly, USA), 1 µg/mL rabbit anti-ZO-1, 0.5 µg/mL mouse 
anti-occludin (Zymed, CA, USA), or 1: 5000 anti-β actin (Sigma, Mannheim, 
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Germany) in 5% BSA in TBS-T overnight at 4°C. Following washing in TBS-T, 
membranes were then incubated with appropriate HRP-conjugated secondary 
antibodies (Bio-rad, Munich, Germany).  The membranes were washed with PBS and 
prepared for enhanced chemiluminescence (GE, Buckinghamshire, UK) according to 
the manufacturer’s instructions. Developed membranes were then exposed to 
hyperfilm-ECL (GE, Buckinghamshire, UK). The films were scanned and protein 
band densities were quantified with the Lab Image software, version 2.71 (Kapelan, 
Leipzig, Germany).  
 
3.3.9 Immunofluorescence microscopy of TJs proteins 
 
Cell monolayers were grown on Lab-Tek™ eight chamber slides (Nunc, 
Naperville, IL, USA) and treated as indicated above. Cells were immunolabelled as 
previously described [321] with some modifications. Briefly, cells were rinsed with 
PBS and fixed in 3.7% formaldehyde at room temperature for 20 min. Cell 
monolayers were then rinsed in PBS and permeabilized in 0.2% Triton X-100 for 7 
min at room temperature. Cells were rinsed in PBS followed by blocking with 1% 
bovine serum albumin (BSA) for 30 min at room temperature. Cells were incubated 
with 3 µg/mL anti-rabbit ZO-1 and 2 µg/mL anti-mouse occludin (Zymed, San 
Francisco, USA) overnight at 4°C. After washing with PBS, cells were incubated with 
anti-rabbit IgG conjugated to Alexa 488 and anti-mouse IgG conjugated to cydye 3 
(Molecular Probes, Eugene, OR, USA) in 1% BSA for 1 hr at room temperature. For 
F actin localization cells were incubated in  0.33 µg/mL of FITC-conjugated phalloidin 
(Sigma-Aldrich, St. Louis, USA) in PBS for 30 min as described previously [322]. 
Cells were also incubated with Hoechst dye (10 µg/mL in PBS) (Molecular Probes, 
Eugene, USA) for 10 minutes to stain nuclei. After washing with PBS, cells were 
mounted using the Dako fluorescence mounting medium (Dako, Carpintera, USA) 
and stored at 4°C in the dark until analyzed. The fluorescence was visualized using 
Axiovert 200M confocal microscope (Carl Zeiss, Jena, Germany). All of the 
fluorescent labelling experiments were repeated four times to ensure reproducibility.  
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3.3.10 Statistics 
 
The data are presented as sample means with error bars indicating the 
standard error of the mean. The p value was calculated using a Student's t test and a 
p value <0.05 was considered statistically significant 
 
3.4 Results 
 
3.4.1 MPA altered TER and TJs permeability in a concentration and 
time dependant manner 
 
In the present study, the effect of MPA on Caco-2 TJ integrity was determined 
by measuring TER and epithelial permeability to the paracellular marker FD4. To 
assess the influence of MPA treatment on TER, cells were incubated with different 
concentrations of MPA (5-100 µmol/L) for up to 72 hr. DMSO did not have any 
significant effect on TER of polarised Caco-2 cell monolayers. Increasing 
concentrations of MPA exhibited concentration- and time-dependant decreases in 
Caco-2 TER (Figure 3.1a). The mean cell monolayer TER decreased from 190.4 to 
181.5, 190.8 to 147.5 and 193.1 to 120.4 Ω.cm2 after 5, 10 and 50 µmol/L MPA 
treatment respectively. The maximal decrease in Caco-2 TER was observed at 100 
µmol/L MPA concentration (86 ± 0.7 Ω.cm2). The decrease in Caco-2 TER increased 
with time between 12 hr and 72 hr (Figure 3.1a).  
Similarly, MPA was associated with a concentration-dependent increase in Caco-2 
paracellular permeability to FD4 (Figure 3.1b). FD4 permeability analysis following 72 
hr MPA treatment showed a concentration-dependant increase in FD4 influx. The 
FD4 influx from the apical to the basolateral chamber was increased 1.5, 2.7, 4.6 and 
7.9 fold after incubation with 5, 10, 50 and 100 µmol/L MPA concentrations 
respectively (Figure 3.1b). 
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Figure 3.1: MPA treatment decreased TER and increased FD4 permeability of Caco-2 cell 
monolayers.    
Caco-2 cells were cultured on filter inserts and grown for 21 days post-confluence to form 
differentiated monolayers. (a) Caco-2 cells were treated with MPA (5-100 µM) for 0-72 hr. MPA 
concentration and time dependent decrease in TER were observed. Graph shows TER (Ω.cm
2
) vs. 
time (hr) with means ± SEM from four independent experiments. (b) Paracellular flux of FD4. Values 
are means of apparent permeability for FD4 (cm/sec) which is the amount of apical FD4 crossing the 
insert membrane per cm
2 
per sec. Bars show SEM and ***=p< 0.0005. 
 
3.4.2 AcMPAG modulation of TER and TJs permeability 
 
To determine whether AcMPAG, a reactive metabolite of MPA, influenced the 
TER and FD4 influx, we incubated Caco-2 cells with AcMPAG (10 µmol/L). A time 
dependant decrease in TER (0 hr: 101.1%, 12 hr: 94.2%, 24 hr: 86.5%, 48 hr: 74.4%, 
72 hr: 67.1% relative to the DMSO control) (Figure 3.2a) was observed after 
incubation with AcMPAG. FD4 influx analysis from apical to basal chamber showed 
that AcMPAG exhibited a mean 2.78 fold increase in FD4 permeability (Figure 3.2b).    
 
 
 
 
 
 
 
 
 55 
a b
 
 
Figure 3.2: AcMPAG treatment caused a time dependant decrease in TER and increase in FD4 
permeability in Caco-2 cell monolayers. 
Caco-2 cells were grown for 21 days post-confluence and treated with AcMPAG (10 µM) for 72 hr 
following which TER (a) and FD4 influx (b) were  determined. Values are means ± SEM of four 
independent experiments. ***=p< 0.0005.  
 
3.4.3 MPA and AcMPAG mediated increase in permeability was not 
due to cell death/apoptosis 
 
To determine whether MPA or AcMPAG induced decreases in TER and 
increased FD4 permeability were due to TJs regulation and not due to the cell death, 
the LDH release from the treated cells was determined. LDH measurement  has 
previously been used as an indicator  of cell death [112]. Exposure to 10 µmol/L MPA 
and 10 µmol/L AcMPAG for up to 72 hr did not result in any significant increase in 
LDH release from the Caco-2 cells (Figure 3.3a).  Furthermore, caspase 3 activity 
was measured to check the effect of MPA or AcMPAG on cell apoptosis. Neither 10 
µmol/L MPA nor 10 µmol/L AcMPAG exposure for 72 hr caused any significant 
apoptosis as compared to DMSO (vehicle) (Figure 3.3b). These findings suggest that 
the TJs disruption caused by MPA/AcMPAG was not associated with cell death or 
apoptosis. 
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Figure 3.3: Effect of MPA and AcMPAG on apoptosis and cell viability in Caco-2 cells. 
Caco-2 were grown for 21 days post-confluence and treated with MPA or AcMPAG for 72 hr. (a) 
Apoptosis was determined by measuring the caspase-3 activity in cell lysates using CaspACE
TM 
Assay 
kits. Caspase 3 activity is expressed as pmol/hr/µg (b) Cell viability was assessed by measuring the 
lactate dehydrogenase (LDH) release in the culture media. Data represent IU/L LDH released into the 
media. Values are presented as the mean ± SEM; of four independent experiments and the 
significance was determined by Student’s t-test.  
 
3.4.4 MPA and AcMPAG increased the expression of MLC2 and 
MLCK in Caco-2 cells 
 
In a previous study we reported that MPA increased the total MLC2 in HEK-
293 cells [323]. Additionally we observed up-regulation of MLCK and ROCK 
expression by MPA in HEK-293 and HT-29 cells (data not shown). In view of these 
findings, we investigated regulation of MLC2 expression and MLCK in Caco-2 cells. 
MLCK is involved in the regulation of barrier function through the phosphorylation of 
MLC2 in response to diverse stimuli [153,324]. In line with the previous findings 
[323], MPA treatment increased the expression of MLC2 at both the mRNA (1.5 fold 
increase) and protein level (1.47 fold increase) in Caco-2 cells (Figure 3.4a and 
Figure 3.4b). AcMPAG (10 µmol/L) exposure for 72 hr, however, increased MLC2 
protein expression (1.68 fold increase) without any significant change in mRNA 
expression. MLCK expression was also up-regulated by MPA (10 µmol/L) at the 
mRNA (1.9 fold) and protein level (2.1 fold). AcMPAG also increased the expression 
of MLCK at the mRNA (1.3 fold increase) and protein (1.7 fold increase) level. ROCK 
expression was significantly regulated by MPA (1.53 fold increase) while AcMPAG 
had no significant effect (Figure 3.4 a). 
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Figure 3.4: Effect of MPA and AcMPAG on MLC2, MLCK and ROCK expression in Caco-2 cells.  
Caco-2 monolayers (21 days post-confluence) were incubated with DMSO (vehicle), MPA (10 µmol/L) 
or AcMPAG (10 µmol/L) for 72 hr. (a) mRNA expression analysis for MLC2, MLCK and ROCK. Total 
RNA was extracted, reverse transcribed and subjected to real time PCR analysis.  EF-2 was used as 
a house keeping gene and the relative mRNA expression of MLC2, MLCK, and ROCK in the MPA, 
AcMPAG and DMSO (vehicle) treated samples was  determined using the comparative threshold 
cycle (CT) method (2
-ΔΔC
T) as described in material and methods. Data indicate the mean of four 
independent experiments ± SEM. (b) Immunoblot analyses for MLC2 and MLCK. Whole cell lysates 
were resolved on 1DE and immunoblotted using MLC2 and MLCK specific antibodies. β actin was 
used as a control for an equal amount of protein load. Densitrometric analysis was done using the Lab 
image software. The data represent mean relative intensities ± SEM from four independent 
immunoblots. *p< 0.05 and **p< 0.005 significance relative to DMSO.  
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3.4.5 MPA and AcMPAG increased MLC2 phosphorylation in Caco-2 
cells 
MLC phosphorylation has been extensively studied with regard to tight 
junction regulation and has been reported to be required for increased paracellular 
permeability [153,184]. To determine whether MPA and AcMPAG caused any defect 
in the epithelial barrier through phosphorylation of MLC2, we checked the 
phosphorylaton of MLC2 using specific phospho-MLC2 antibody. MPA and AcMPAG 
treatment (10 µmol/L each) for 72 hr increased the expression of phospho-MLC2 by 
2.8 and 2.3 fold respectively (Figure 3.5).  
 
 
 
 
 
 
 
 
 
Figure 3.5: Effect of MPA and AcMPAG on the phosphorylation of MLC2 in Caco-2 cells. 
Caco-2 monolayers (21 days post-confluent) were incubated with either vehicle (DMSO), MPA or 
AcMPAG (10 µmol/L each) for 72 hr. Whole cell lysates were resolved on 1DE and immunoblotting 
was performed using a specific phospho-MLC2 antibody. β actin was used as a loading control for 
equal amount of protein load. Densitrometric analyses were done using the Lab image software. The 
representative data are average of relative intensities ± SEM from four independent immunoblot. 
**=p< 0.005.  
 
3.4.6 MPA and AcMPAG altered TJ proteins expression and 
distribution  
The modulatory effect of MPA on TJs proteins, ZO-1 and occludin was 
investigated by immunofluorescent labelling. Changes in the distribution and 
expression of occludin and ZO-1 can be used as the markers for determination of 
TJs disruption which has been implicated in several GI tract diseases [147,325].  
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Figure 3.6: Effects of MPA and AcMPAG on ZO-1 and occludin distribution. 
 
Caco-2 cells were grown for 21 days post-confluence and treated with DMSO (vehicle), MPA or 
AcMPAG for 72 hr. Cells were fixed, permeated, and stained for ZO-1 and occludin, as described in 
materials and methods section. Figure shows the distribution of ZO-1 and occludin in Caco-2 cells 
exposed to DMSO (vehicle) (a, b, and c), 10 µmol/L MPA (d, e, and f) alone, 10 µmol/L AcMPAG (g, h, 
and i). Cells were doubled stained for ZO-1 (a, d, g) and occludin (b, e, h). An overlay (ZO-1, occludin, 
DAPI) is shown in the right panel (c, f, i). Corresponding proteins were detected with secondary 
antibodies conjugated with either FITC 488 (green; ZO-1) or cydye 3 (red; occludin). DAPI (blue; 
nuclei) was used to stain nuclei. Images were examined using confocal microscopy. Images presented 
are representative images of 5 independent experiments. 
 
Confocal analyses of ZO-1 and occludin distribution showed uniform and continuous 
staining at the plasma membrane in control cells (DMSO) (Fig 3.6 (a-c)). MPA and 
AcMPAG treatment (10 µmol/L) for 72 hr led to redistribution of ZO-1 and occludin 
proteins.  The most prominent features were disappearance of staining at the cellular 
periphery, with aggregation and paracellular openings between the adjacent cells 
(MPA: Figure 3.6 (d-f), AcMPAG: Figure 3.6 (g-i)). These microscopic alterations at 
the apical cellular borders correlated with the amount of increased TJs permeability 
(Figure 3.1 and Figure 3.2) observed.  
g 
h i 
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We further investigated whether MPA or AcMPAG quantitatively altered the 
expression of TJs proteins in Caco-2 cells. Immunoblot analysis showed that 10 
µmol/L of both MPA and AcMPAG decreased the expression of occludin by 2.1 and 
2.7 fold respectively (Figure 3.7). These expressional changes are consistent with 
the immunostaining of occludin protein which also revealed disappearance and 
redistribution of occludin protein from the membranes (Figure 3.6).  
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Effect of MPA and AcMPAG on occludin protein expression in Caco-2 cells. 
Cell were grown to 21 days post-confluency and then treated for 72 hr with DMSO (vehicle), MPA or 
AcMPAG (10 µmol/L each). Whole cell lysates were extracted, separated on 1-DE and occludin 
detected using specific antibody as mentioned in the methods section. Four independent experiments 
were carried out and results represent mean ± SEM. *=P< 0.05, **=P< 0.05. 
 
 
3.4.7 MPA and AcMPAG modulation of Caco-2 F-actin 
 
The perijunctional ring of F-actin is the fundamental unit of the actin 
cytoskeleton that supports the tight junction and thus plays an important role in 
barrier regulation [326]. Structural alterations of the F-actin-based cytoskeleton are 
used to detect changes in actin and tight junctions [327,328].  
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Figure 3.8: MPA and AcMPAG-induced remodelling of the F-actin cytoskeleton. 
Caco-2 cells grown to 21 days post-confluence followed by 72 hr treatment with DMSO (a, b), 10 
µmol/L MPA (c, d) and 10 µmol/L AcMPAG (e, f). Cells were fixed, permeated, and F-actin was 
stained with FITC-phalloidin (red) and nuclei were stained with DAPI (blue), as described in methods 
section. Fluorescence images were obtained using Axiovert 200M confocal microscope. Images are 
representative of 4 independent experiments.  
 
To investigate whether MPA or AcMPAG mediated colonic epithelial barrier 
disruption was associated with structural modulation of the F-actin cytoskeleton, we 
stained Caco-2 cells with FITC-labelled phalloidin, a commonly used fluorescent 
marker for F- actin [322,328]. In the vehicle control (DMSO) cell monolayers, the F-
actin cytoskeleton was uniformly organized as shown in figure 3.8 (a-c). Following 72 
hr exposure to 10 µmol/L of either MPA (Figure 3.8 d-f) or AcMPAG (Figure 3.8 g-i), 
the uniform distribution of actin staining in epithelial cells appeared disrupted and 
was marked by randomly distributed dense patches of staining, which suggest 
disruption of the actin cytoskeleton as a possible mechanism for the alterations in the 
TJs by MPA and AcMPAG.  
 
 
 62 
3.4.8 MPA-mediated increase in MLC phosphorylation through 
MLCK 
To analyze for the possible involvement of MLCK in the MPA mediated TJs 
disruption, we determined the effect of MPA on total protein expression of MLC2, 
MLCK, and phospho-expression of MLC2 in the presence of ML-7 (Figure 3.9). ML-7 
acts as a selective antagonist of MLCK by competing for its ATP-binding site and 
reverses the effects of agents involved in TJs disruptions [328].  Previously it was 
reported that ML-7 had  no significant effect on total MLC2 and MLCK expression 
and that ML-7 mainly affects the phosphorylation of MLC2 by decreasing the activity 
of MLCK [112]. In the present study, expressional analysis showed that MPA 
treatment in the presence of ML-7 did not alter total MLC2 and MLCK expression, 
which was observed after MPA treatment alone.  Additionally, we observed that the 
presence of ML-7 in the medium was able to reverse the effect of MPA on MLC2 
phosphorylation (Figure 3.9). To further validate these results, cells were incubated 
with CD which is an actin-disrupting drug that has previously been reported to 
increase MLC2 phosphorylation [329]. Our results also showed that CD increased 
phospho-MLC2 expression; which is consistent with the previous report [329]. 
 
In the present study, expressional analysis showed that MPA treatment in the 
presence of ML-7 did not alter total MLC2 and MLCK expression, which was 
observed after MPA treatment alone.  Additionally, we observed that the presence of 
ML-7 in the medium was able to reverse the effect of MPA on MLC2 phosphorylation 
(Figure 3.9). To further validate these results, cells were incubated with CD which is 
an actin-disrupting drug that has previously been reported to increase MLC2 
phosphorylation [329]. Our results also showed that CD increased phospho-MLC2 
expression; which is consistent with the previous report [329]. 
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Figure 3.9: Effect of ML-7 on MPA-mediated increases in MLC2, MLCK and MLC 
phosphorylation. 
Caco-2 monolayers (21 days post-confluent) were incubated with either vehicle (DMSO), MPA, 
MPA+ML-7, or CD for 72 hr. Total cell proteins were isolated and equal amount of protein was loaded 
resolved on 1DE. Expression was analysed by immunoblot analysis using antibodies against MLC2, 
MLCK and p-MLC2. Beta actin was used as a control for an equal amount of protein load. Bands were 
quantified using the Lab image software. The data represent the mean of 4 independent experiments 
± SEM. *=p< 0.05, **=p< 0.005. 
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3.4.9 MLCK inhibition partially prevented MPA effects on TER and 
permeability 
To investigate whether MPA mediated TJs alteration is through effects on 
MLCK, we pre-treated Caco-2 monolayers with ML-7 for 1 hr and then co-incubated 
them with (10 µmol/L) MPA for the indicated time periods. It was previously reported 
that ML-7 prevents TJs disrupting agent mediated decreases in TER and increases 
the permeability via inhibition of MLCK [153,328]. Co-treatment with ML-7 and MPA 
resulted in a significant higher TER as compared to cells treated with MPA alone. 
Similarly, apical to basal FD4 influx was also reduced in cells co-treated with MPA 
and ML-7 (Figure 3.10). CD was previously reported to decrease TER and increase 
permeability [330]. In the following experiments, similar to MPA, CD treated cells 
showed significant decreases in TER and increases in FD4 influx (Figure 3.10). 
These findings suggest that the MPA-induced increases in Caco-2 TJ permeability 
are at least partly the result of a mechanism closely associated with MLCK 
expression and activity.  
 
 
 
 
Figure3.10: ML-7 co-treatment reversed the effect of MPA on TER and permeability. 
Cells were grown to 21 days post-confluence and incubated with MPA or MPA+ML-7, or CD for 72 hr. 
The effects on (a) TER and (b) FD-4 influx were measured as described in the methods section. ML-7 
a specific MLCK inhibitor prevented both the MPA-mediated increase in FD 4 paracellular diffusion 
and the decreases in TER. Data are the mean ± SEM of at least four independent experiments. **=p< 
0.005, ***=p< 0.0005. 
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3.4.10 Inhibition of MLCK prevented MPA mediated alteration of TJ 
proteins 
We examined the involvement of MLCK in MPA mediated TJs regulation 
using immunofluorescence methods. Previously it was reported that the redistribution 
of TJs proteins by TJs disrupting agents can be reversed by inhibiting MLCK 
[215,331,332]. Immunofluorescence localization of occludin and ZO-1 showed that 
ML-7 could partly prevent  redistribution of ZO-1 and occludin induced by MPA 
exposure (Figure 3.11 d-f)  when compared to cells treated with MPA alone (Figure 
3.11 a-c). 
 
 
Figure 3.11: ML-7 co-treatment reversed the effect of MPA on distribution of TJs proteins. 
Cells following 21 days post-confluency were treated with MPA, and CD or pre-treated with ML-7 
followed by MPA treatment. Cells were labelled with florescent antibodies specific for ZO-1 and 
occludin. Figure shows ZO-1 (a, g, j), occludin (b, h, k) and an overlay of ZO-1 and occludin along with 
DAPI stained nuclei (c, i, l). Four independent experiments were performed.  
 
ML-7 co-treatment induced reassembly of the ZO-1 and occludin at the cellular 
borders with reclosure of the paracellular gaps (Figure 3.11 g-i). The MPA induced 
disruption of TJs proteins distribution was prevented by an MLCK inhibitor (ML-7), 
indicating that the downstream alteration of TJs proteins is dependent on MLCK 
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activation. In contrast, CD, like MPA, disrupts the distribution of ZO-1 and occludin as 
shown by disappearance of these proteins from the paracellular membrane (Figure 
3.11 j-l) 
 
We also performed immunoblot analysis for occludin protein expression. 
Results showed that ML-7 was able to reverse the effect of MPA on occludin 
expression by increasing its expression by 1.92 fold as compared to cells treated with 
MPA alone. CD treatment showed a 3.2 fold decrease in occludin protein as 
compared to DMSO control (Figure 3.12). 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Effect of ML-7 co-treatment with MPA on occludin protein expression in Caco-2 
cells. 
Caco-2 cell monolayers following 21 days post-confluency were incubated with DMSO, MPA (10 
µmol/L), MPA (10 µmol/L) +ML-7 (10 µmol/L) or CD (10 µmol/L) for 72 hr. Protein extracts were 
immunoblotted for occludin and β-actin. Densitrometric measurement was done with the Lab image 
software. Values are means ± SEM (n = 4). 
 
3.5 Discussion 
Intestinal cells form a  crucial physical and functional barrier, which regulates 
the movement of water, electrolytes, nutrients, and xenobiotics [333]. The 
gastrointestinal tract is directly involved in the metabolism and transport of various 
endogenous and exogenous compounds [334]. Several intestinal diseases are 
characterized by barrier dysfunction including inflammatory bowel disease, graft 
versus host disease, and infectious enterocolitis (reviewed in [335]). It has been 
previously reported that epithelial barrier defects lead to increased intestinal 
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permeability and the development of diarrhoea in human patients with bowel 
diseases [336] and in mouse models [337].  
MPA associated gastrointestinal adverse effects are a major concern in 
transplantation medicine  and diarrhoea is the most frequent unwanted clinical 
outcome following treatment with MPA regimes [338]. Previous reports showed that 
MPA is associated with gastrointestinal mucosal injury [60,65,311,339,340]. The 
effect of therapeutic concentrations of MPA on the gastrointestinal epithelial barrier is 
not well described. Diverse physiological and pathophysiological stimuli cause 
intestinal barrier dysfunction, regulated via several pathways such as those involving 
protein kinase C, protein kinase A, MLCK, Rho-kinase, mitogen-activated protein 
kinases, and phosphoinositide 3-kinase. Disturbances in these pathways can all lead 
to the alteration in TJs protein expression and distribution [181,303]. In a previous 
study, we observed a significant increase in the MLC2 expression in HEK-293 cells 
following MPA exposure [323]. MLC2 phosphorylation via MLCK and/or ROCK has 
been implicated in several barrier disorders [329].  
To better understand the possible mechanism of MPA mediated TJs regulation, 
we used Caco-2 monolayers as a colonic model [341]. The present study 
demonstrates for the first time in vitro that MPA, at non-toxic and therapeutic 
concentrations produces a significant modulation of intestinal epithelial barrier 
function in Caco-2 cells. The Caco-2 cell line is widely used as an in vitro intestinal 
barrier cell model, which exhibits a well differentiated brush border, TJs and intestinal 
proteins [341,342]. MPA exposure increased TJs permeability and impaired TJ 
proteins (ZO-1 and occludin) expression and distribution. On the other hand, the 
MPA concentrations used did not cause significant apoptosis or cell death, 
suggesting that the effects of MPA on GI barrier function are the result of a non-
cytotoxic mechanism.  
Previously it was shown that MLCK activity in Caco-2 cells triggers a series of 
molecular processes such as induction of MLC phosphorylation, myosin-Mg2+-
ATPase activation, and perijunctional actin-myosin interaction which are responsible 
for actin filament disruption leading to Caco-2 epithelial barrier opening [328]. Several 
agents increase MLCK mediated MLC2 phosphorylation which disrupts tight junction 
proteins, leading to the increased TJs permeability implicated in barrier associated 
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diseases [184]. We investigated the possible disruptive role of MPA on epithelial 
barrier permeability and attempted to link this effect with MLCK-induced MLC-2 
phosphorylation. 
 
To demonstrate the effect of MPA and one of its active metabolites, AcMPAG, 
on barrier properties of this colonic model, Caco-2 cells were exposed to non-
cytotoxic concentrations of MPA (10 µmol/L) and AcMPAG (10 µmol/L) followed by 
measurements of TER and influx of markers. Determination of TER and influx of 
permeability markers are widely used techniques to assess  the integrity and 
permeability of monolayers [343] because TJs disruption can be reflected by the 
reduction in TER and the increase in influx of permeability markers [335]. 
 
Our data revealed that MPA and AcMPAG increased Caco-2 cell monolayer 
permeability as shown by decreases in TER and increases in FD4 influx (Fig 1).  
These findings are in agreement with another report on the effects of MMF (an ester 
prodrug of MPA) on the barrier function of small bowel and distal colon of Wistar rats 
[344].   
 
TJs proteins, ZO-1, and occludin are protein markers which are widely used to 
investigate TJs integrity [184,345]. These proteins maintain structure and function of 
TJs integrity which are vital for normal intestinal architecture [97,148]. The 
disturbance in the distribution and expression of these proteins has been observed in 
intestinal barrier disorders [150,313]. In the present study, we investigated the effect 
of MPA and AcMPAG on the distribution and expression of ZO-1 and occludin. We 
found that exposure of Caco-2 monolayers (21-days post-confluency) to therapeutic, 
non-cytotoxic concentrations of MPA and AcMPAG for 72 hr led to a decrease in the 
expression of occludin proteins, as evidenced by Western blot analysis (Figure 3.7). 
Under normal conditions ZO-1 and occludin are generally present at the pericellular 
boundary, and distributed homogeneously, presenting a characteristic feature of 
intact TJs structure.  Disruption and redistribution of TJs proteins has been reported 
previously in several studies that suggested that alteration in these proteins can lead 
to hyperpermeability [184,346]. MLCK mediated MLC-2 phosphorylation (involved in 
modulation of ZO-1 and occludin morphologically and biochemically) can induce an 
increase in TJs permeability [184,184].  
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Furthermore, we also demonstrated that MPA and AcMPAG exposure changed 
the distribution of ZO-1 and occludin proteins, as revealed by a discontinuous pattern 
of immunofluorescent staining of these TJs proteins (Figure 3.5). To investigate 
whether MLCK was involved in MPA modulation of TJs, we used a specific MLCK 
inhibitor , ML-7 which is a selective antagonists of MLCK [347]. Previously it was 
reported that inhibition of MLCK mediated MLC phosphorylation by ML-7 can prevent 
or reverse TJs barrier losses induced by several agents such as TNFα, Cytochalasin 
B, and ethanol [112,153,328,348]. To investigate the effect of MPA on MLCK activity, 
we pre-incubated cell monolayers with ML-7 followed by MPA exposure. Results 
showed that ML-7 could at least partially reverse the MPA mediated decrease in TER 
as well as the increase in FD4 influx. Additionally, ML-7 was able to prevent the MPA 
induced redistribution and decrease in expression of ZO-1 and occludin proteins.          
 
Treatment with CD, a known stimulant of MLCK and actin-depolymerising agent 
[329] which was used as positive control for the effects of MPA treatment, also 
showed a decrease in TER and increase in paracellular flux (Figure 3.10). 
Previously, it was reported that CD was able to increase MLCK activity and MLC2 
phosphorylation [329], which our results confirmed. In addition, we found that CD 
was able to alter the expression and distribution of TJs proteins   which is  consistent 
with results of a  previous study of CD treated epithelial cells [349]. These results 
showed that both CD and MPA decreased TER and disrupted the actin cytoskeleton.  
The present study revealed that inhibition of MLCK activity by ML-7 significantly 
prevented the MPA mediated increase in MLC2 phosphorylation with no significant 
effect on total MLCK and MLC2 expression.  
 
MLC2 phosphorylation has a key role in maintaining TJs integrity by regulating 
actomyosin contraction [153]. Several pathways were described previously which 
regulate the phosphorylation of MLC2; among them Rho-kinase and MLCK signalling 
are widely studied in the context of barrier defects [191]. MLCK is involved in the 
regulation of barrier function by phosphorylation of MLC2 in response to diverse 
stimuli [153,324]. ML-7 via MLCK inhibition prevents the disruption of both occludin 
and actin, which demonstrates the importance of MLCK activity in TJs physiology 
[350]. Our results suggest that increases in MLCK might be responsible for the MPA 
induced redistribution of ZO-1 and occludin in Caco-2 monolayers.  
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3.6 Conclusion 
 
The present study indicates that MPA and its active AcMPAG metabolite at 
therapeutic concentrations produce functional alterations in TJs of Caco-2 cells 
resulting in abnormal TJs permeability, and redistribution of TJs proteins including 
disturbance and displacement of F-actin. These data suggest that MPA mediated 
increases in permeability required increased MLCK activity which could be reversed 
by ML-7. While requiring further investigation, MLCK inhibition by ML-7 significantly 
reduced the effect of MPA exposure on TJs disruption, thus suggesting a pivotal role 
of MLCK in regulating TJs barrier properties. These findings provide new insights into 
the mechanism by which therapeutic use of MPA may alter intestinal epithelial barrier 
functions and suggest mechanisms which may be responsible for some of the GI 
adverse effects associated with MPA.   
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4.  Summary  
Mycophenolic acid (MPA) is a potent inhibitor of inosine monophosphate 
dehydrogenase (IMPDH), a key regulator of purine biosynthesis. MPA is frequently 
used as an immunosuppressant drug to prevent acute graft rejection for kidney, liver 
and lung transplantation. The use of MPA is associated with GI toxicity which is a 
problem to the patients, and a challenge for clinicians. The present study was 
undertaken to identify novel molecular targets of MPA using a proteomics approach 
(Figure 4.1). Two dimensional gel electrophoresis (2-DE) and mass spectrometry 
were used to identify proteome alterations in human embryonic cells (HEK-293) 
following exposure to therapeutic concentrations of MPA. Cells were treated for 72 
hours, and total cell lysate was resolved by 2-DE followed by QTOF-MS/MS analysis 
of all identified differentially regulated proteins. A total of 12 proteins were 
differentially regulated in HEK-293 cells following exposure to MPA. Among these, 7 
proteins were up-regulated (complement component 1 Q subcomponent-binding 
protein, electron transfer flavoprotein subunit beta, cytochrome b-c1 complex subunit, 
peroxiredoxin 1, thioredoxin domain-containing protein 12, myosin regulatory light 
chain 2, and profilin 1), while 5 proteins were down-regulated (protein SET, stathmin, 
40S ribosomal protein S12, histone H2B type 1 A, and histone H2B type 1-
C/E/F/G/I). Functional annotation tool analysis showed that MPA modulated proteins 
were mainly involved in the cytoskeleton (26%), chromatin structure/dynamics (17%), 
and energy production/conversion (17%). Considering both putative functions and 
their clinical significance, peroxiredoxin-1 (Prdx-1) and myosin light chain 2 (MLC2) 
were selected for Western blot and real time PCR analysis. Both proteins showed up-
regulation at mRNA as well as at protein level following MPA exposure.  
 
MLC2 is known to be involved in several functions including tight junctions (TJ) 
regulation. Epithelial barrier disruption by phosphorylation of MLC2 has been 
implicated in several bowel diseases. Since MPA treatment often causes diarrhea 
when used clinically, we hypothesized that MPA regulated epithelial TJ by 
modulation of MLC2. To test this hypothesis, we investigated the effect of MPA on 
the expression of MLC2 in two colonic cell lines, HT-29 and Caco-2. Increased MLC2 
expression was observed in both cell lines following MPA exposure. These findings 
suggest that the increase in MLC2 expression after exposure to MPA is not a cell 
specific effect. Moreover, we observed similar up-regulation of MLC2 expression in 
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whole cell lysates prepared from MMF treated rats, which implies that MPA has 
similar effects both in vitro and in vivo.  
We then used Caco-2 cells grown for 21 days post confluence to develop 
polarize monolayers to conduct physiological, expressional and microscopic analysis 
to establish the possible role of MPA in disruption of TJ (Figure 4.1). MPA exposure 
caused a time and dose dependent decreases in transepithelial resistance (TER), 
and increases in the FITC-dextran 4 KDa (FD4) paracellular influx in these Caco-2 
monolayers. In addition, we found that AcMPAG (a pharmacologically active 
metabolite of MPA) was also able to cause decreases in TER and increases in FD4 
influx. These MPA and AcMPAG mediated increases in permeability were not due to 
cellular toxicity, as shown by the fact that no significant apoptosis or cell death was 
observed. In MPA and AcMPAG treated cells, we also found altered expression and 
distribution of TJ proteins (ZO-1 and occludin).  
Since MLC phosphorylation is a key modulator of TJ disruption; we investigated 
whether MPA also increased MLC2 phosphorylation. Using immunoblot analysis we 
found that MPA significantly increased MLC2 phosphorylation. We then investigated 
whether MPA mediated increases in MLC2 phosphorylation was through effects on 
MLCK. Immunoblot analysis revealed that MPA increased MLCK expression both at 
mRNA and protein levels. To further confirm that MLCK was the key player in MPA 
mediated MLC2 phosphorylation and its associated TJ disruption, we pre-incubated 
cells with ML-7 (a specific MLCK inhibitor), and observed that ML-7 was able to 
partially prevent the MPA mediated increase in MLC2 phosphorylation. Furthermore, 
we found that ML-7 partially reversed MPA mediated decreases in TER, and 
increases in FD4 paracellular influx. ML-7 also prevented the MPA associated 
disruption of the distribution and expression of TJ proteins (Figure 4.2). These 
findings suggest that MPA may regulate TJ function via MLCK-driven MLC2 
phosphorylation. However, these results do not exclude the possibility that other 
pathways may also be involved in MPA induced regulation of TJ function.  
Taking together findings of the present studies showed that therapeutic 
concentrations of MPA can modulate the expression of important proteins which are 
crucial for various cellular functions. MPA may modulate epithelial TJ integrity via 
MLC2 phosphorylation. These findings will be helpful to understand the molecular 
mechanisms of MPA-induced proteome alterations, including proteins that are 
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involved in disruption of TJ. Further studies are needed to clarify the mechanism(s) 
and consequences of MPA mediated disruption of TJs, especially in in vivo models, 
to know whether these TJ barrier changes are responsible for the GI adverse events 
associated with MPA treatment. 
 
 
 
 
Figure 4.1: A proteomic approach for identification of novel MPA molecular targets.  
HEK-293 cells were cultured, treated with MPA, whole cell lysates was resolved using 2-DE, and silver 
stained. Protein spots were densitometrically analysed and differentially expressed proteins were 
subjected to in-gel digestion and identified by QTOF-MS/MS. The up-regulation of MLC2 by MPA was 
further confirmed by immunoblot analysis. The functional involvement of MLC2 in MPA mediated 
barrier defects was determined by physiological assays such as TER and paracellular influx of FITC-
dextran using Caco-2 cells monolayers. In addition, the expression and distribution of TJ proteins (ZO-
1 and occludin) were also investigated using immunoblotting and immunoflurecence microscopy.  
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Figure 4.2: Proposed model of MPA mediated TJ distruption.  
MPA increased MLCK-mediated MLC2 phosphorylation in Caco-2 cell monolayers. MLC2 
phosphorylation altered the expression and distribution of TJ proteins (ZO-1 and occludin) that have 
been identified as a key factor in the development of barrier defects seen in several intestinal 
diseases. MLC2 phosphorylation also alters the distribution of F actin filaments and the associated TJ 
disruption results in decreases in TER and increases in paracellular influx. In the present study we 
observed that MPA disrupted TJ, was associated with increased MLCK expression, and MLC2 
phosphorylation. We therefore propose that MPA associated TJ disturbance is dependant on MLCK-
driven MLC phosphorylation that leads to decreased expression and redistribution of TJ proteins. Pre-
treatment with ML-7 (a specific inhibitor of MLCK) partially prevented the MPA mediated increase in 
MLC2 phosphorylation, disturbance of TJ proteins, and increase in permeability. We hypothesized that 
the observed increase in paracellular permeability following MPA treatment is due to TJ disruption 
caused by MLC2 phosphorylation, which mediates alterations in the expression and distribution of TJ 
proteins.  
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6. Appendix  
 
Figure 5.1: A graphical representation of relative abundance (% volume) of all differentially 
regulated proteins.  
Relative abundance of the proteins differentially expressed in DMSO and MPA treated HEK-293 cells. 
Results shown as mean of four independent experiments (*p < 0.05 or **p < 0.005). 
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                Table 5.1: MS/MS analysis table of all differentially regulated proteins.  
 
Spot no: the spot identification number on 2-DE; Accession no: Swiss-prot protein identification 
number; Sequence coverage: the percentage of the protein's sequence represented by the peptides 
identified by MS/MS; MS/MS analysis: peptides sequences (bold & red) identified for a particular 
protein, including MS/MS queries, and the MS/MS sepectra of an exemplary peptide.  
 
 
 
Spot no. 
 
Accessi
on no. 
 
 
Sequence 
Coverage 
 
Protein name 
 
MS/MS Analysis 
 
6 Q01105 11 Protein SET 1 MAPKRQSPLP PQKKKPRPPP ALGPEETSAS AGLPKKGEKE QQEAIEHIDE 
51 VQNEIDRLNE QASEEILKVE QKYNKLRQPF FQKRSELIAK IPNFWVTTFV 
101 NHPQVSALLG EEDEEALHYL TRVEVTEFED IKSGYRIDFY FDENPYFENK 
151 VLSKEFHLNE SGDPSSKSTE IKWKSGKDLT KRSSQTQNKA SRKRQHEEPE 
201 SFFTWFTDHS DAGADELGEV IKDDIWPNPL QYYLVPDMDD EEGEGEEDDD 
251 DDEEEEGLED IDEEGDEDEG EEDEDDDEGE EGEEDEGEDD 
Start-End  Observed   Mr(expt)   Mr(calc)       Delta     Miss   Sequence 
58 - 68       637.3448  1272.6750  1272.6561     0.0190     0     R.LNEQASEEILK.V 
123 - 132   604.8156  1207.6166  1207.5972     0.0194     0     R.VEVTEFEDIK.S 
155 - 167   482.8923  1445.6551  1445.6423     0.0128     0     K.EFHLNESGDPSSK.S 
MS/MS Fragmentation of VEVTEFEDIK 
 
 
 
 
9 Q07021 
 
9 
 
Complement component 
1 Q subcomponent-
binding protein, 
mitochondrial 
1 MLPLLRCVPR VLGSSVAGLR AAAPASPFRQ LLQPAPRLCT RPFGLLSVRA 
51 GSERRPGLLR PRGPCACGCG CGSLHTDGDK AFVDFLSDEI KEERKIQKHK 
101 TLPKMSGGWE LELNGTEAKL VRKVAGEKIT VTFNINNSIP PTFDGEEEPS 
151 QGQKVEEQEP ELTSTPNFVV EVIKNDDGKK ALVLDCHYPE DEVGQEDEAE 
201 SDIFSIREVS FQSTGESEWK DTNYTLNTDS LDWALYDHLM DFLADRGVDN 
251 TFADELVELS TALEHQEYIT FLEDLKSFVK SQ 
Start -End   Observed    Mr(expt)   Mr(calc)     Delta     Miss Sequence 
105-119       819.3414  1636.6682  1636.7403    -0.0720     0  
K.MSGGWELELNGTEAK.L     208 - 220     757.3118  1512.6090  1512.6732    -0.0642     
0  R.EVSFQSTGESEWK.    
208 - 220     757.3123  1512.6100  1512.6732    -0.0632     0  R.EVSFQSTGESEWK.D 
MS/MS Fragmentation of EVSFQSTGESEWK 
 
 
 
 
14 P38117 22 Electron transfer 
flavoprotein subunit beta 
1 MAELRVLVAV KRVIDYAVKI RVKPDRTGVV TDGVKHSMNP FCEIAVEEAV 
51 RLKEKKLVKE VIAVSCGPAQ CQETIRTALA MGADRGIHVE VPPAEAERLG 
101 PLQVARVLAK LAEKEKVDLV LLGKQAIDDD CNQTGQMTAG FLDWPQGTFA 
151 SQVTLEGDKL KVEREIDGGL ETLRLKLPAV VTADLRLNEP RYATLPNIMK 
201 AKKKKIEVIK PGDLGVDLTS KLSVISVEDP PQRTAGVKVE TTEDLVAKLK 
251 EIGRI 
Start-End  Observed   Mr(expt)   Mr(calc)       Delta     Miss   Sequence 
27 - 35       438.2605   874.5064   874.4760     0.0304     0    R.TGVVTDGVK.H 
77 - 85       461.2477   920.4808   920.4386     0.0423     0    R.TALAMGADR.G   
99 - 106     427.2842   852.5538   852.5181     0.0357     0    R.LGPLQVAR.V 
165 - 174   551.8152  1101.6158  1101.5666   0.0493     0    R.EIDGGLETLR.L 
222 - 233   670.3985  1338.7824  1338.7143   0.0681     0    K.LSVISVEDPPQR.T 
239 - 248   552.8170  1103.6194  1103.5710   0.0484     0    K.VETTEDLVAK.L 
MS/MS Fragmentation of LSVISVEDPPQR 
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15 P47985 
 
16 Cytochrome b-c1 
complex subunit Rieske, 
mitochondrial 
 
1 MLSVASRSGP FAPVLSATSR GVAGALRPLV QATVPATPEQ PVLDLKRPFL 
51 SRESLSGQAV RRPLVASVGL NVPASVCYSH TDIKVPDFSE YRRLEVLDST 
101 KSSRESSEAR KGFSYLVTGV TTVGVAYAAK NAVTQFVSSM SASADVLALA 
151 KIEIKLSDIP EGKNMAFKWR GKPLFVRHRT QKEIEQEAAV ELSQLRDPQH 
201 DLDRVKKPEW VILIGVCTHL GCVPIANAGD FGGYYCPCHG SHYDASGRIR 
251 LGPAPLNLEV PTYEFTSDDM VIVG 
Start-End  Observed    Mr(expt)   Mr(calc)    Delta   Miss    Sequence 
85 - 92      506.7550  1011.4954  1011.4662   0.0293     0      K.VPDFSEYR.R 
93 - 101    530.8184  1059.6222  1059.5924   0.0298     1      R.RLEVLDSTK.S 
94 - 101    452.7524    903.4902   903.4913   -0.0011     0     R.LEVLDSTK.S 
171 - 177  408.7669    815.5192   815.5018    0.0175     0     R.GKPLFVR.H 
183 - 196  807.9452  1613.8758 1613.8260    0.0498     0     K.EIEQEAAVELSQLR.D 
197 - 204  498.2446    994.4746   994.4468    0.0278     0     R.DPQHDLDR.V 
MS/MS Fragmentation of DPQHDLDR 
 
 
 
 
 
18 Q06830 10 Peroxiredoxin-1 1 MSSGNAKIGH PAPNFKATAV MPDGQFKDIS LSDYKGKYVV FFFYPLDFTF 
51 VCPTEIIAFS DRAEEFKKLN CQVIGASVDS HFCHLAWVNT PKKQGGLGPM 
101 NIPLVSDPKR TIAQDYGVLK ADEGISFRGL FIIDDKGILR QITVNDLPVG 
151 RSVDETLRLV QAFQFTDKHG EVCPAGWKPG SDTIKPDVQK SKEYFSKQK 
Start-End  Observed    Mr(expt)   Mr(calc)    Delta   Miss  Sequence 
111 - 120   554.2855  1106.5564  1106.5972   -0.0407   0   R.TIAQDYGVLK.A 
141 - 151   606.3233  1210.6320  1210.6670   -0.0349   0   R.QITVNDLPVGR.S  
MS/MS Fragmentation of TIAQDYGVLK. 
 
 
 
 
 
 
 
22 P16949 18 Stathmin 1 MASSDIQVKE LEKRASGQAF ELILSPRSKE SVPEFPLSPP KKKDLSLEEI 
51 QKKLEAAEER RKSHEAEVLK QLAEKREHEK EVLQKAIEEN NNFSKMAEEK 
101 LTHKMEANKE NREAQMAAKL ERLREKDKHI EEVRKNKESK DPADETEAD 
Start-End  Observed    Mr(expt)   Mr(calc)    Delta     Miss  Sequence 
44 - 52      537.7797   1073.5448  1073.5604    -0.0156   0    K.DLSLEEIQK. 
53 - 60      473.2399    944.4652    944.4927    -0.0274    1    K.KLEAAEER.R   
86 - 95      583.2628  1164.5110  1164.5411     -0.0300   0    K.AIEENNNFSK.M   
MS/MS Fragmentation of AIEENNNFSK 
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23 O95881 13 Thioredoxin domain-
containing protein 12 
1 METRPRLGAT CLLGFSFLLL VISSDGHNGL GKGFGDHIHW RTLEDGKKEA  
51 AASGLPLMVI IHKSWCGACK ALKPKFAEST EISELSHNFV MVNLEDEEEP  
101 KDEDFSPDGG YIPRILFLDP SGKVHPEIIN ENGNPSYKYF YVSAEQVVQG  
151 MKEAQERLTG DAFRKKHLED EL 
Start-End   Observed    Mr(expt)   Mr(calc)     Delta   Miss  Sequence 
115 - 123     495.3159   988.6172   988.5593     0.0579     0    R.ILFLDPSGK.V      
115 - 123     495.3221   988.6296   988.5593     0.0703     0    R.ILFLDPSGK.V 
139 - 152     832.9714  1663.9282  1663.7916   0.1367     0    K.YFYVSAEQVVQGMK.E     
139 - 152     832.9721  1663.9296  1663.7916   0.1381     0    K.YFYVSAEQVVQGMK.E   
MS/MS Fragmentation of YFYVSAEQVVQGMK 
 
 
 
 
24 O14950 23 Myosin regulatory light 
chain MRLC2 
1 MSSKKAKTKT TKKRPQRATS NVFAMFDQSQ IQEFKEAFNM IDQNRDGFID 
51 KEDLHDMLAS LGKNPTDAYL DAMMNEAPGP INFTMFLTMF GEKLNGTDPE 
101 DVIRNAFACF DEEATGTIQE DYLRELLTTM GDRFTDEEVD ELYREAPIDK 
151 KGNFNYIEFT RILKHGAKDK DD 
Start - End  Observed  Mr(expt)   Mr(calc)     Delta     Miss Sequence 
  94 - 104     614.8414  1227.6682  1227.6095   0.0587     0   K.LNGTDPEDVIR.N 
125 - 133     526.2847  1050.5548  1050.5016   0.0533     0   R.ELLTTMGDR.F   
134 - 144     708.3533  1414.6920  1414.6252   0.0668     0   R.FTDEEVDELYR.E 
152 - 161     630.8325  1259.6504  1259.5935   0.0570     0   K.GNFNYIEFTR.I 
MS/MS Fragmentation of LNGTDPEDVIR 
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27 Q96A08 12 Histone H2B type 1-A 1 MPEVSSKGAT ISKKGFKKAV VKTQKKEGKK RKRTRKESYS IYIYKVLKQV 
51 HPDTGISSKA MSIMNSFVTD IFERIASEAS RLAHYSKRST ISSREIQTAV 
101 RLLLPGELAK HAVSEGTKAV TKYTSSK 
Start - End     Observed  Mr(expt)   Mr(calc)     Delta   Miss  Sequence 
    95 - 101     408.7352   815.4558   815.4501    0.0057     0   R.EIQTAVR.L   
  102 - 110     477.3018   952.5890   952.5957   -0.0066     0   R.LLLPGELAK. 
 MS/MS Fragmentation of LLLPGELAK 
 
 
 
 
28 P62807 57 Histone H2B type 1-
C/E/F/G/I 
1 MPEPAKSAPA PKKGSKKAVT KAQKKDGKKR KRSRKESYSV YVYKVLKQVH 
51 PDTGISSKAM GIMNSFVNDI FERIAGEASR LAHYNKRSTI TSREIQTAVR 
101 LLLPGELAKH AVSEGTKAVT KYTSK 
Start - End     Observed    Mr(expt)   Mr(calc)     Delta   Miss Sequence 
    36 - 44      569.2944  1136.5742    1136.5390     0.0353     0  K.ESYSVYVYK.V 
    45 - 58      503.6217  1507.8433    1507.8358     0.0074     1  
K.VLKQVHPDTGISSK.A 
    48 - 58      584.8140  1167.6134    1167.5884     0.0250     0  K.QVHPDTGISSK.A 
    59 - 73      888.4241  1774.8336    1774.8018     0.0318     0  
K.AMGIMNSFVNDIFER.I   
    88 - 100    487.9460  1460.8162    1460.7947     0.0215     1  R.STITSREIQTAVR.L 
    94 - 100    408.7277   815.4408     815.4501      -0.0093     0  R.EIQTAVR.L 
   101 - 109   477.2920   952.5694     952.5957      -0.0262     0  R.LLLPGELAK.H 
   101 - 109   477.3095   952.6044     952.5957       0.0088     0  R.LLLPGELAK.H 
   110 - 121   409.8952  1226.6638    1226.6619     0.0019     1  K.HAVSEGTKAVTK.Y 
MS/MS Fragmentation of STITSREIQTAVR 
 
 
 
 
31 P25398 14 40S ribosomal protein 
S12 
1 MAEEGIAAGG VMDVNTALQE VLKTALIHDG LARGIREAAK ALDKRQAHLC 
51 VLASNCDEPM YVKLVEALCA EHQINLIKVD DNKKLGEWVG LCKIDREGKP 
101 RKVVGCSCVV VKDYGKESQA KDVIEEYFKC KK 
Start - End     Observed    Mr(expt)   Mr(calc)       Delta    Miss Sequence 
    24 - 33      533.7745     1065.5344  1065.5931   -0.0586   0    K.TALIHDGLAR.G  ) 
    24 - 33      533.7747     1065.5348  1065.5931   -0.0582   0    K.TALIHDGLAR.G  
    85 - 93      531.2432     1060.4718  1060.5376    0.0657   0    K.LGEWVGLCK.I   
MS/MS Fragmentation of LGEWVGLCK 
 
 
 
 105 
34 P07737 53 Profilin-1 1 MAGWNAYIDN LMADGTCQDA AIVGYKDSPS VWAAVPGKTF VNITPAEVGV 
51 LVGKDRSSFY VNGLTLGGQK CSVIRDSLLQ DGEFSMDLRT KSTGGAPTFN 
101 VTVTKTDKTL VLLMGKEGVH GGLINKKCYE MASHLRRSQY 
Start - End  Observed    Mr(expt)   Mr(calc)      Delta   Miss  Sequence 
   39 - 54      822.4751  1642.9356  1642.9294     0.0062     0  
K.TFVNITPAEVGVLVGK.D   
   76 - 89      813.3810  1624.7474  1624.7403     0.0072     0  R.DSLLQDGEFSMDLR.T   
   92 - 105    690.3588  1378.7030  1378.7093    -0.0062     0  K.STGGAPTFNVTVTK.  
 106 -  116   609.8624  1217.7102  1217.7053     0.0049     1  K.TDKTLVLLMGK.E   
 117 - 127    576.3310  1150.6474  1150.6458     0.0016     1  K.EGVHGGLINKK.C   
 128 -  136   583.7573  1165.5000  1165.5008    -0.0008     0  K.CYEMASHLR.R   
MS/MS Fragmentation of TFVNITPAEVGVLVGK 
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